Design and prototype of an external quality assurance program for urine bicarbonate by Benjamin, Ryan
Design and prototype of an external
quality assurance program for urine
bicarbonate
minor dissertation submitted in partial fulfilment of the





Division of Chemical Pathology
Clinical and Laboratory Sciences
Faculty of Health Sciences






Division of Chemical Pathology
Department of Clinical Laboratory Sciences, Faculty of Health Sciences
University of Cape Town and NHLS Groote Schuur Hospital
Dr. P. Berman
MBChB, MMed
Division of Chemical Pathology
Department of Clinical Laboratory Sciences, Faculty of Health Sciences
University of Cape Town and NHLS Groote Schuur Hospital
This research report is based on my own independent work and has neither
as a whole nor in part been, is being or is to be submitted for another
degree at any other university. Furthermore, this work has not been
published prior to registration for this degree.
Ryan Benjamin
Abstract
This dissertation validates a Beckman-Coulter DxC R© assay for total bicar-
bonate in urine and then proceeds to design, prototype and cost an inter-
laboratory comparison (ILC) program for the above urine bicarbonate based
on the validation. Furthermore, this work serves as a case study for how to
establish proficiency testing – and thereby achieve accreditation – for tests
without external quality assurance because of analyte instability.
Urine bicarbonate analysis forms part of the diagnostic workup of renal
tubular acidosis (RTA). The differential diagnosis of wasting and stunting
includes RTA. Given an incidence of wasted and stunted children of 250 000
per annum in South Africa, one should anticipate that at least this many
appropriate urine bicarbonates should be requested per annum – thus estab-
lishing a need for urine bicarbonate analysis. The provision of urine bicar-
bonate analysis as an accredited clinical laboratory test requires validation
and quality assurance. The absence of proficiency testing for urine bicarbon-
ate diminishes this quality assurance and establishes a problem.
The dissertation also reviews the pathophysiology and diagnosis of RTA.
Furthermore, it compares and contrasts the traditional and physicochemical
clinical acid-base theories and introduces non-protoncentric acid-base theo-
ries.
The study shows that the Beckman-Coulter DxC R© assay for total bi-
carbonate in urine has a functional sensitivity of 5mmol/L. The intra-
laboratory coefficient of variation at 10mmol/L is 18%. The reference range
was calculated to be 2− 4mmol/L.
The ILC program is based on the recovery of total carbon dioxide from
urine spiked with sodium bicarbonate. The results are analysed using stan-
dard deviation index plots and Youden plots.
For the ILC administering body, the marginal cost of producing the qual-
ity control samples and analysing the laboratory results is R4, 64 per ILC
cycle – this is the minimum subscription to the ILC. For the laboratory
being evaluated, the marginal cost of the ILC is the subscription plus the
marginal cost of analysis. On an arterial blood gas analyser, the marginal
cost of analysis is zero and thus the marginal cost of the ILC is R4, 64. The
marginal cost of analysis on the Beckman-Coulter DxC R© is R13, 00 per qual-
ity control cycle and thus (for the laboratory being evaluated) the minimum
marginal cost of the ILC is R17, 64.
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Dissertation notation
All equations are scalar and, where numbered, are identified by chapter name and
number where the latter is chronological. Equation references are placed in brack-
ets. Thus the 5th equation in section D1 will be designated (D1−5). The symbols
in all equations are italicised.
Similarly, all numbered reactions are identified by chapter and number but are
placed in angled brackets. Thus the 2nd reaction in chapter B would be < B−2 >.
The symbols within chemical reactions are also italicised.
In Appendix D1, in an attempt to explain various acid-base theories, two vo-
cabularies are constructed. The first vocabulary relates to the description of a
phenomenon and the second relates to the explanation of a phenomenon. Conse-
quently, acid-base phenomena are separated into description and explanation.
A patient sample is collected from an individual. The aliquots from a patient
sample are specimens. A sample consists of several specimens. Furthermore, a
sample represents a collection of specimens from the population such that if a
specimen was collected from every individual, within the population, that sample
would be the population.

The Road Not Taken
Two roads diverged in a yellow wood,
And sorry I could not travel both
And be one traveler, long I stood
And looked down one as far as I could
To where it bent in the undergrowth;
Then took the other, as just as fair,
And having perhaps the better claim,
Because it was grassy and wanted wear;
Though as for that the passing there
Had worn them really about the same,
And both that morning equally lay
In leaves no step had trodden black.
Oh, I marked the first for another day!
Yet knowing how way leads on to way,
I doubted if I should ever come back.
I shall be telling this with a sigh
Somewhere ages and ages hence:
Two roads diverged in a wood, and I –
I took the one less traveled by,
And that has made all the difference.
Robert Frost
Contents
List of Figures IX
List of Tables XII
Abbreviations XVI
A Research Protocol for MMed Dissertation 1
A.1 Summary of proposal for the design of external quality control pro-
gram for urinary bicarbonate . . . . . . . . . . . . . . . . . . . . . 1
A.1.1 Raison d’être . . . . . . . . . . . . . . . . . . . . . . . . . . 1
A.1.2 Study design . . . . . . . . . . . . . . . . . . . . . . . . . . 2
A.2 Proposal for the design of external quality control program for uri-
nary bicarbonate . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
A.3 Details of test validation and external quality assurance . . . . . . 6
A.3.1 Determining the analytical performance . . . . . . . . . . . 6
A.3.2 Design of the external quality assurance program . . . . . . 9
A.3.3 The interference experiment . . . . . . . . . . . . . . . . . . 9
A.3.4 Costing for the experiment . . . . . . . . . . . . . . . . . . 10
A.3.5 Operating procedure . . . . . . . . . . . . . . . . . . . . . . 11
A.3.6 Test schedule . . . . . . . . . . . . . . . . . . . . . . . . . . 13
IV
A.3.7 Project summary . . . . . . . . . . . . . . . . . . . . . . . . 16
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
B Literature Review 20
B.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
B.2 Search strategy and quality criteria . . . . . . . . . . . . . . . . . . 20
B.3 Renal tubular acidosis . . . . . . . . . . . . . . . . . . . . . . . . . 21
B.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . 21
B.3.2 Historical taxonomy . . . . . . . . . . . . . . . . . . . . . . 22
B.3.3 Clinical presentation and basic investigation . . . . . . . . . 24
B.3.4 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . 26
B.3.5 Pathology and molecular basis of disease . . . . . . . . . . . 26
B.3.5.1 The proximal tubule and primary inherited RTA II 26
B.3.5.2 The distal tubule, intercalcated cells and primary
inherited RTA I . . . . . . . . . . . . . . . . . . . 28
B.3.5.3 The cortical collecting duct, the principal cell and
primary inherited RTA IV . . . . . . . . . . . . . 29
B.3.5.4 The loop of Henle and ammonium secretion . . . . 30
B.3.5.5 CA II deficiency and RTA III . . . . . . . . . . . . 31
B.3.6 Pathological basis of classification . . . . . . . . . . . . . . 33
B.3.7 Diagnostic algorithms . . . . . . . . . . . . . . . . . . . . . 35
B.3.8 Laboratory investigation . . . . . . . . . . . . . . . . . . . . 38
B.4 The physicochemical acid-base theory, RTA and bicarbonate profi-
ciency testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
B.5 Further research required . . . . . . . . . . . . . . . . . . . . . . . 40
B.6 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
C Manuscript 48
C.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
C.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
C.3 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . 52
C.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
C.4.1 Comparison between sodium bicarbonate and ammonium bi-
carbonate . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
C.4.2 Stability experiments . . . . . . . . . . . . . . . . . . . . . . 58
C.4.3 Blood gas analysis comparison . . . . . . . . . . . . . . . . 60
C.4.4 Functional sensitivity . . . . . . . . . . . . . . . . . . . . . 62
C.4.5 Recovery difference experiments . . . . . . . . . . . . . . . 64
C.4.6 Reference range . . . . . . . . . . . . . . . . . . . . . . . . . 65
C.4.7 Summary of urinary bicarbonate analysis validation . . . . 66
C.5 Proficiency testing design . . . . . . . . . . . . . . . . . . . . . . . 67
C.6 Prototype results . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
C.7 Discussion of pilot study of the ILC program . . . . . . . . . . . . 73
C.8 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
C.9 Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . S-1
S-1 Recovery difference: proof of concept . . . . . . . . . . . . . . . . . S-1
S-2 Proficiency testing costing . . . . . . . . . . . . . . . . . . . . . . . S-2
S-3 Tabular summaries of raw data . . . . . . . . . . . . . . . . . . . . S-4
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S-8
D Supporting documentation D-1
Appendix D1: An introduction to clinical acid-base theory D1-2
D1.1 Nomenclature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D1-3
D1.2 History of acid-base theory . . . . . . . . . . . . . . . . . . . . . . D1-4
D1.3 Traditional acid-base theory in clinical chemistry . . . . . . . . . . D1-4
D1.4 Evaluating Stewart’s contribution . . . . . . . . . . . . . . . . . . . D1-7
D1.4.1 Acid-base model type . . . . . . . . . . . . . . . . . . . . . D1-8
D1.4.2 Stewart theory physiology . . . . . . . . . . . . . . . . . . . D1-10
D1.4.3 Application of Stewart theory . . . . . . . . . . . . . . . . . D1-11
D1.5 Closing comments . . . . . . . . . . . . . . . . . . . . . . . . . . . D1-14
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D1-16
Appendix D2: Dissertation proofs D2-21
D2.1 Proof that independent variables do not imply and are not implied
by regulated factors . . . . . . . . . . . . . . . . . . . . . . . . . . D2-21
D2.2 Proof that dependent variables do not imply and are not implied by
unregulated factors . . . . . . . . . . . . . . . . . . . . . . . . . . . D2-22
D2.3 Proof that Stewart’s theory is not a special case of Lewis acid-base
theory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D2-23
D2.4 Proof that the number of potential states can be increased arbitrarilyD2-23
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D2-23
Appendix D3: Lewis acid-base theory D3-25
D3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D3-25
D3.2 Proof that H+ is a Lewis acid . . . . . . . . . . . . . . . . . . . . . D3-26
D3.3 Proof that Lewis acids are acidic . . . . . . . . . . . . . . . . . . . D3-27
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D3-27
Appendix D4: Urine bicarbonate decision limits D4-28
D4.1 Calculation of urine bicarbonate decision limit . . . . . . . . . . . D4-28
D4.2 Calculation of double urine bicarbonate decision limit . . . . . . . D4-29
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D4-29
Appendix D5: Funding D5-30
Appendix D6: Consent form D6-32
Appendix D7: Ethics approval D7-35
Appendix D8: Author instructions D8-38
Appendix D9: External quality assurance forms D9-47
D9-1 Proficiency testing instruction sheet . . . . . . . . . . . . . . . . . D9-47
D9-2 External quality assurance program report . . . . . . . . . . . . . . D9-49
List of Figures
A.1 Urine aliquots for [HCO−3 ] stratified by temperature and
time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
B.1 Basic algorithm for distinguishing between the categories
of renal tubular acidosis . . . . . . . . . . . . . . . . . . . . . 24
B.2 Proximal tubular cell H+ regulatory pathways . . . . . . 27
B.3 Regulation of H+ by the α-intercalcated cell . . . . . . 28
B.4 Role of the principal cell in renal tubular acidosis IV . 29
B.5 The fate of ammonia and ammonium in the nephron . . . . 31
B.6 Potential mechanisms for the role of NH3 in acid-base
regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
B.7 Diagnostic algorithm for confirming renal tubular aci-
dosis in metabolic acidosis . . . . . . . . . . . . . . . . . . . . 36
B.8 Hyperkalaemic renal tubular acidosis diagnostic algo-
rithm – only increased potassium emphasized . . . . . . . . 36
B.9 Renal tubular acidosis IV diagnostic algorithm . . . . . . 37
B.10 Diagnostic algorithm for renal stones . . . . . . . . . . . . 38
C.1 The effect of acidification on bicarbonate species . . . . 52
IX
C.2 The aliquots of the original urine patient sample re-
quired for spiking . . . . . . . . . . . . . . . . . . . . . . . . . . 54
C.3 Recovery (immediately after spiking) of bicarbonate added
to urine specimens . . . . . . . . . . . . . . . . . . . . . . . . . 56
C.4 Recovery ratio of bicarbonate by solution type (analysis
performed immediately post spiking) . . . . . . . . . . . . . . 57
C.5 Effect of temperature on the stability of ammonium bi-
carbonate after 2 hours for the 3 decision levels . . . . 58
C.6 Effect of temperature on the stability of ammonium bi-
carbonate after 24 hours for the 3 decision levels . . . 59
C.7 Effect of storage time on the stability of ammonium bi-
carbonate stored at room temperature for the 3 deci-
sion levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
C.8 Effect of storage time on the stability of refrigerated
ammonium bicarbonate for the 3 decision levels . . . . . . 60
C.9 24 hour ammonium bicarbonate recovery on the DxC and
ABG analysers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
C.10 The measurement of difference in recovery . . . . . . . . 64
C.11 Reference range determination . . . . . . . . . . . . . . . . 65
C.12 Youden plot for total CO2 . . . . . . . . . . . . . . . . . . . 71
C.13 Total CO2 upper difference standard deviation index plot 72
C.14 Total CO2 lower difference standard deviation index plot 73
C.15 Total CO2 upper difference recovery . . . . . . . . . . . . 74
C.16 Total CO2 lower difference recovery . . . . . . . . . . . . 74
D1-1Venn diagram comparing the number of compartments de-
scribed by various models . . . . . . . . . . . . . . . . . . . . D1-9
D1-2Venn diagram comparing the clinical chemistry models
to the physical chemistry acid-base theories . . . . . . . . D1-10
D1-3Venn diagram of clinical scenarios to which the various
acid-base approaches should apply . . . . . . . . . . . . . . . D1-13
List of Tables
A.1 Number of specimens tested, initially, for bicar-
bonate concentration – stratified by factor of de-
cision limit . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
A.2 Number of specimens for the decision limit and half
decision limit – stratified by temperature and time
of analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
A.3 Masses of NH4CO3 and NaHCO3 spiked into urine
to achieve specimen decision limit levels . . . . . . . 13
A.4 Table of tests conducted stratified by day and
time of day . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
A.5 Alternative protocol of number of specimens tested,
initially, for bicarbonate concentration – strati-
fied by factor of decision limit . . . . . . . . . . . . . . 15
A.6 Alternative table of tests conducted stratified by
day and time of day . . . . . . . . . . . . . . . . . . . . . 15
B.1 Synonymous terms and analogous categories in the
classification of renal tubular acidosis in 1972 . . . 22
XII
B.2 Classification of renal tubular acidosis in 2002 and
basic urine and serum investigations for diagnosis . 23
B.3 Clinical presentations in renal tubular acidosis types 25
B.4 Classification of renal tubular acidosis and some
primary causes . . . . . . . . . . . . . . . . . . . . . . . . . 32
B.5 Taxonomy-pathophysiology correlation in renal tubu-
lar acidosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
C.1 Intra-assay precision data for bicarbonate: Com-
parison between NaHCO3 and NH4HCO3 . . . . . . . . 62
C.2 Comparison of alternative assessment procedures
for proficiency testing . . . . . . . . . . . . . . . . . . . 68
C.3 Maximum allowable difference between bicarbon-
ate duplicates in proficiency testing program . . . . 70
S-1 Description of NH4CO3 vs NaHCO3 HCO3 concen-
tration comparison data . . . . . . . . . . . . . . . . . . S-4
S-2 Summary of paired student t-test comparison be-
tween NH4CO3 and NaHCO3 bicarbonate concen-
trations by decision level . . . . . . . . . . . . . . . . . S-5
S-3 Descriptive and inferential data for the effect
of storage temperature on bicarbonate recovery
stratified by decision limit . . . . . . . . . . . . . . . . . S-6
S-4 Descriptive and inferential data for the effect of
storage time on bicarbonate recovery stratified
by decision limit . . . . . . . . . . . . . . . . . . . . . . . . S-6
S-5 Description of ABG and DxC TCO2 concentration
comparison data . . . . . . . . . . . . . . . . . . . . . . . . S-7
S-6 Summary of Wilcoxon-test comparison between ABG
and DxC bicarbonate concentrations by decision
level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S-7
D1-1 Similar terms in the descriptive and explanatory
spaces . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D1-3
D1-2Classification of primary acid-base disturbances by














AAP Alternate assessment proce-
dures
ABG Arterial blood gas
AD Autosomal dominant
AE1 Anion exchanger 1







CAH Congenital adrenal hyperpla-
sia
CAII Carbonic anhydrase II
CCD Cortical collecting duct
CDC Center for Disease Control
CI Confidence interval
CLSI Clinical and Laboratory
Standards Institute
CV Coefficient of variation
DCT Distal convoluted tubule
DFTT Dynamic functions test
ENaC Epithelial sodium channel
EQA External quality assurance
Fe(HCO−3 ) Fractional excretion of bicar-
bonate
FTT Failure to thrive
ILC Interlaboratory comparison
XVI
ISE ion selective electrode
kAE Kidney anion exchanger
kNBC Kidney sodium-bicarbonate
co-transporter
LoB Limit of the blank
LoD Limit of detection
M Median
N Normal
NAE Net acid excretion - titrate-
able acid +NH+4 −HCO
−
3
NCCLS National Committee for Clin-
ical Laboratory Standards
NHE-3 Sodium-hydrogen exchanger
pCO2 Partial pressure of carbon
dioxide
pH Negative logarithm, to the
base ten, of the hydrogen ion
concentration
pK Dissociation constant







ROMK Renal outer medullary potas-
sium channel
RT Room temperature
RTA Renal tubular acidosis
SAG Serum anion gap
SBE Standard base excess
SD Standard deviation
SDS Standard deviation of a sam-
ple obtained by measur-
ing the individual specimens
within the sample
SDpool Standard deviation of sam-
ple consisting of pooled spec-
imens
SDI Standard deviation index
SID Strong ion difference
SIG Strong ion gap
tCO2 Total carbon dioxide




UAG Urine anion gap
UOG Urine osmolar gap
WNK1 With no lysine

A. Research Protocol for
MMed Dissertation
Three documents (summary of study, a proposal and a detailed proposal)
were submitted to the Research Ethics Committee and the Clinical Labo-
ratory Sciences Departmental Research Committee for review as per their
guidelines.
A.1 Summary of proposal for the design of
external quality control program for uri-
nary bicarbonate
A.1.1 Raison d’être
The diagnosis and management of renal tubular acidosis (RTA) is inexpen-
sive. RTA may present with failure to thrive (FTT) and current opinion is
that every child with FTT should be investigated for RTA.
One can calculate that in South Africa 500 000 newly diagnosed children
with FTT should be identified per annum, of whom 250 000 are stunted or
wasted. Thus, a need to screen for RTA exists. The benefit to the individual
is both physical and psychological, the diagnosis may spare society the cost
of more specialised investigation and, academically, it should facilitate the
1
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determination of the epidemiology of this pathology.
Laboratories in South Africa should offer, but are reluctant to perform,
the diagnostic tests (which include urinary bicarbonate) because the avail-
able methods/calculations – total CO2 (tCO2) and bicarbonate on a blood
gas analyser – have not been validated for urine and no external quality as-
surance exists. By performing the test, the laboratory risks withdrawal of
accreditation and cannot allow the clinician to make confident diagnoses.
The construction of an external quality assurance program for urine bi-
carbonate will allow laboratories to assist in the diagnosis of renal tubular
acidosis. An external quality assurance program will facilitate screening of
the at-risk population, will allow the epidemiology to be explored and the
benefit of diagnosis to be determined. Furthermore, the test should be readily
accessible through-out the country wherever blood gas analysers are used.
A.1.2 Study design
The study can be divided into two components. The first is experimental
and the second is design.
The experimental component can further be divided into two. The first
is the validation of the method and the second determines whether commer-
cially available analytical grade ammonium bicarbonate and sodium bicar-
bonate can be used as external quality control material.
The design component uses the experimental data to design an external
quality assurance program that is accessible, safe and cost effective for the
country. Factors that will be considered are storage, transport, labour and
3
consequently cost.
A.2 Proposal for the design of external qual-
ity control program for urinary bicar-
bonate
Renal tubular acidosis is generally accepted to be a rare condition due to
failure of the kidney to acidify the urine appropriately. Epidemiological data
for the condition are, however, not available. The pathology should be con-
sidered in all cases of FTT[1].
Harrison[2] reports Nannan et al.’s[3] findings that in 1999, of the South
African children in the age group 12 to 71 months, 48.7% were at least un-
derweight. Of these children, 27.6% were either stunted or wasted. The
census data for 2009 indicate that 10% of the South African population
(5 000 000)[4] is under the age of 5 years. One should therefore anticipate
that 250 000 new stunted or wasted children should be identified annually.
Consequently, 250 000 children should be tested for RTA.
Of the tests used to diagnose and classify RTA[1], urine bicarbonate anal-
ysis cannot be implemented by the laboratory partly because the bicarbonate
assay is not validated for urine and partly because no external quality assur-
ance (EQA) program exists for urinary bicarbonate. The websites of all the
EQA programs on a Center for Disease Control (CDC) list of EQA programs
worldwide were used to determine whether an EQA schedule for urinary bi-
carbonate exists[5]. Such a schedule was not found.
Given the apparent need for the screening for RTA, based on the epidemi-
4
ology of FTT, it is proposed that an EQA program for urine bicarbonate be
instituted. Given that (by definition) proficiency testing compares laboratory
results to that of the group and/or with an assigned value[6], it is proposed
that the same recovery experiment (using commercially available ammonium
bicarbonate) be performed by different laboratories and the results used for
interlaboratory comparison and/or comparison to the assigned value. Thus
the recovery results would form the basis of performance assessment in the
proficiency testing program.
The dissertation can be divided into two components. The first is vali-
dation which requires the characterisation of the analytical performance of
the test methods. The second component is the design of an EQA program.
Several questions have to be answered with regard to the EQA program.
For the validation of the method, standard protocols as documented
by the Clinical and Laboratory Standards Institute (CLSI), formerly Na-
tional Committee for Clinical Laboratory Standards (NCCLS), will be im-
plemented. The protocols for analytical performance protocols are deter-
mination of the limit of detection (LoD)[7], the functional sensitivity[7],
linearity[8] and intra-assay coefficient of variation (CV) at the clinical de-
cision limits[9]. A recovery experiment[10, 11] and an interference experi-
ment using sodium[11, 12] will determine the accuracy and specificity of the
method. Finally a reference range[13, 14] for urinary bicarbonate will be
established to determine population variation. Given that only 20 specimens
will be used, it may not be possible to establish a reference range. Although
one would anticipate that the variability will be minimal in which case the
confidence intervals may be sufficiently small, allowing the use of only 20 spec-
imens, it has already been demonstrated that the inter-individual variability
is sufficiently large such that more than 20 specimens will be required[15].
5
An engineering design approach[16] will be used to construct an EQA pro-
gram for urinary bicarbonate. The purpose of EQA is to ensure conformity
of measurement[17]. Recovery experiments[11] using commercially available
preparations of bicarbonate will form the basis of the EQA – thus ensuring
conformity with a particular commercial manufacturer.
Before considering the bicarbonate compound to spike in the recovery
experiment, it should be noted that at present two theories for acid-base
phenomena are used in clinical chemistry[18–20]. The conventional theory is
based on the Henderson-Hasselbalch equation[21] and the newer theory is the
physico-chemical theory of acid-base[22]. The two acid-base theories predict
different pHs depending on the compound added. This is important when
calculating total CO2 on an arterial blood gas analyser where total CO2 is
calculated from pH and the partial pressure of CO2.
It is proposed that a commercial preparation of ammonium bicarbonate
(NH4HCO3) of known purity be used as the EQA substrate. There are,
however, advantages to using sodium bicarbonate (NaHCO3). Ammonium
bicarbonate is volatile and requires storage in a cool, dry and well-ventilated
place away from moisture, heat and sunlight. Ammonium bicarbonate may
also be an irritant to the skin. These restrictions do not exist for sodium
bicarbonate. The cost of both preparations is not significant but it is noted
that sodium bicarbonate is less expensive. The sodium in NaHCO3 does,
however, have a significant effect in the physico-chemical theory and it also
affects the value of the dissociation constant (pK) of H2CO3 on which the
Henderson-Hasselbalch equation depends[23, 24]. Thus, one of the questions
to be answered is whether using NaHCO3 as EQA material as compared to
NH4HCO3 is different. The data generated will be used to design and cost
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an EQA program for urine bicarbonate which will be available for the country.
There are at least two methods used to determine the bicarbonate. The
first uses a blood gas analyser and the Henderson-Hasselbalch equation to
determine the bicarbonate(HCO−3 ) based on the pH, pCO2 and pK[25]. The
second method acidifies the urine converting all the HCO−3 to CO2 and then
measuring the total CO2 (tCO2)[26]. These methods must be compared to
determine whether the EQA results are comparable. The latter method is
used by the Beckman-Coulter DxC R© analyser evaluated in this document.
The latter method does not depend on pH and should thus be independent
of acid-base theory.
A.3 Details of test validation and external
quality assurance
The experiments to be performed are divided into
1. determining the analytical performance and
2. design of external quality assurance.
The analyser to be used for the experiments is the Beckman-Coulter DxC R©.
A.3.1 Determining the analytical performance
Thirty millilitres of mid-stream urine from each of 20 healthy adult control
subjects will be collected. The sample standard deviation (SDS)[9] of bicar-
bonate will be determined based on these 20 specimens within the sample.
The 95th centile of these results will be used to determine the limit of the
blank (LoB)[7]. Five millilitre aliquots of the 20 specimens will then be
pooled and the standard deviation of the pooled sample (SDpool) will be de-
termined by measuring the pooled sample 60 times[7]. The limit of detection
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(LoD) will be calculated from SDpool and LoB[7].
The baseline bicarbonate levels of the specimens were measured to deter-
mine the LoB. The 20 specimens will be spiked with a bicarbonate compound
such that the bicarbonate is at double the clinical decision limit, the clinical
decision limit (27mmol/L as calculated in Appendix D4.1) and half the clin-
ical decision limit – where the clinical decision limit is defined by a fractional
excretion of bicarbonate of 5%[1]. The resultant bicarbonate in the speci-
mens will be measured immediately and aliquots of these specimens will be
stored at 4 oC and room temperature (RT). Each of these stored specimens
will be measured at 2h and at 1 day. The bicarbonate in the individual
specimens will be measured and the paired student t-test will be used to de-
termine whether a significant change in the (temperature and storage-time
stratified) samples has occurred. A less stringent reference change value anal-
ysis will also be performed. The standard deviation at the clinical decision
limits will thus have been established and the stability at the above bicar-
bonate concentrations. A power function will be fitted to the data for the
tests performed immediately (unspiked, spiked with half the decision limit,
spiked with the decision limit and spiked with double the decision limit) in
order to estimate the concentration at which the CV is 20% – the functional
sensitivity[7]. Only 15 specimens will be tested at double the decision limit
because the most important function of this level is to determine the linear-
ity. Furthermore, the spiked specimens in which the bicarbonate is analysed
immediately will only be aliquoted into different temperature groups after
the initial measurement. The number of specimens analysed at time t = 0
stratified by concentration is summarised in Table A.1 below.
It is recognised that the 20 specimens analysed at 0 bicarbonate are included
in the calculation of the LoB described above. Thus, only an additional 50
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Fraction of bicarbonate decision limit 0 0.5 1.0 2.0
Number of specimens in each sample 20 20 20 15
Table A.1: Number of specimens tested, initially, for bicarbon-
ate concentration – stratified by factor of decision limit
specimens will be analysed initially at these bicarbonate concentrations.
Given that the stability at zero bicarbonate concentration will not be
determined, only the half critical limit sample, the critical limit sample and
double the critical limit sample will be analysed at 2h and 1 day. The tests
to be analysed are tabulated in Table A.2 below. Thus a total of 160 speci-
menss will be processed.
4 oC RT
2 h 20 20
1 day 20 20
Table A.2: Number of specimens for the decision limit and half
decision limit – stratified by temperature and time of analysis
RT: room temperature
The final component of the stability experiment is the number of speci-
mens for the concentration that is double the clinical decision limit. Fifteen
specimens will be analysed at t = 0. Four aliquots of each specimen will be
analysed at 4 oC and RT at 2h and 1 day for a total of 75 specimens – 15 of
which have already been tallied in Table A.1.
The data used to determine the stability above will also be used to es-
tablish linearity to double the clinical decision limit[8]. Thus only the inter-
ference experiment remains to complete the establishment of the analytical
performance.
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A.3.2 Design of the external quality assurance pro-
gram
The first experiment will determine whether conformity exists between the
commercially manufactured (and established) amount of ammonium bicar-
bonate and the amount determined by our analyser. The data for the tests
performed immediately (unspiked, spiked with half the decision limit, spiked
with the decision limit and spiked with double the decision limit) will be
used in a recovery experiment[11]. The data will be analysed using linear
regression, absolute and relative difference plots and paired student t-tests.
The same recovery experiments will be performed using sodium bicar-
bonate spiked into the specimens at the same concentration as the equivalent
ammonium bicarbonate. Thus 20 specimens at each of three levels (unspiked,
spiked with half the clinical decision limit and spiked with the clinical de-
cision limit) and 10 specimens spiked with double the clinical decision limit
will have recovery experiments performed on them[11]. The results will be
compared directly to the manufacturer using linear regression, absolute and
relative difference plots and paired student t-tests as above. The paired stu-
dent t-test will also be used between the ammonium bicarbonate recovery
results and the sodium bicarbonate recovery results to determine whether a
difference exists between these samples.
A.3.3 The interference experiment
Sodium will be tested in the interference experiment[12]. Sodium has been
selected because it alters the pK in the Henderson-Hasselbalch equation[23]
and is a strong ion in the physico-chemical theory of acid-base equilibria[22].
The data from the EQA comparison described above will be used for the
sodium interference experiment. The difference will be compared to the ac-
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ceptable difference as described by Westgard[11]. The more stringent criteria
of the NCCLS will also be used[12].
A.3.4 Costing for the experiment
All purchases will be from Sigma-Aldrich R©. The cost of 1 kg analytical grade
ammonium bicarbonate (product number 11213-1KG-R) isR 176, 00[27]. The
cost of 1 kg analytical grade sodium bicarbonate (product number 13433-
1KG-R) is R 160, 00[27]. An arbitrary figure of R 100.00 has been assigned
for miscellaneous consumables such as wooden tongue depressors.
The total number of tests performed will be 410. The allocation of tests
is as indicated below. Twenty tests will be performed to determine the LoB
and 60 more tests to establish the LoD and CV. Thus, for the basic analytical
performance, 80 tests will be performed.
The stability analysis will require a total of 295 tests. Given that 20 of
the tests are used for the LoB, only an additional 275 tests will be performed
for the stability analysis.
One hundred and thirty tests will be performed for the EQA analysis but
more than half of these tests will form part of the stability experiment. Thus,
only an additional 55 tests will be required to complete the EQA analysis.
A total of 130 tests will be required to perform the interference exper-
iments but these will all be part of the stability experiment and thus no
additional tests will have to be performed.
The cost of an individual test is R35, 39. Thus the cost of performing
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the experiments is R14 509.90. The cost of the consumables is R436. The
anticipated total cost is thus R14 945.90.
A.3.5 Operating procedure
A table will be constructed with specimen numbers as first column, concen-
tration on the first row, temperature in the second column and time in the
third column. An ice pack will be available for temporary specimen storage.
Each patient sample will have five 1.5ml microcentrifuge tubes labeled with
a temperature (4 oC or RT), a time (0min, 2h or 1 day), a concentration













































1.5ml urine added to eah miroentrifuge tube
half deision limit
Figure A.1: Urine aliquots for [HCO−3 ], stratified by temperature
and time – RT: room temperature
Note that the 0min specimen does not have an assigned temperature.
The 4 oC microcentrifuge tubes will be stored on the ice pack.
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It has been shown that it is not necessary to collect the urine under
mineral oil if it is to be analysed within 2h[15]. The wide variability of
normal urine bicarbonate levels has been demonstrated[15]. It is therefore
improbable that the 20 specimens will be adequate for a reference range.
Nevertheless, for the reference range, a funnel will be used to collect urine
directly into a test tube (minimising the exposed surface area) as previously
described[15]. However, for the analytical and recovery experiments, mid-
stream urines will be collected into standard urine collection containers and
time will be allowed for equilibrium to be reached. During and after spiking
(with ammonium bicarbonate or sodium bicarbonate), all specimens will be
stored in volumetric flasks to minimise the exposed surface area.
From every subject (20) 30ml of urine will be collected. Aliquots of
200µL will be used to measure tCO2 immediately on the Beckman-Coulter
DxC R© analyser. One ml of urine from each sample will be pooled immedi-
ately. The bicarbonate concentration of forty 100µL aliquots of the pooled
sample will then be measured.
For the half decision limit, decision limit and double decision limit sam-
ple levels, each of 3 aliquots of 7.5ml of urine from each patient sample was
spiked with either 8mg, 16mg or 32mg of ammonium bicarbonate, respec-
tively (Table A.3). This corresponds to 56mg of ammonium bicarbonate per
patient sample or 1.12 g of ammonium bicarbonate in total. From the above
aliquots, 1.5ml aliquots will be stored in the appropriate microcentrifuge
tube. These specimens will be assayed at the appropriate times.
For the interference experiment, 1.7mg of sodium bicarbonate will be dis-
solved in 1.5ml urine for half the decision limit sample level, 3.4mg sodium
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Specimen Decision 0.5 1.0 2.0 Mass/patient Total
limit level sample
NH4CO3 added to urine (mg) 8 16 32 56 1 120
NaHCO3 added to urine (mg) 1.7 3.4 6.8 11.9 238
Table A.3: Masses of NH4CO3 and NaHCO3 spiked into urine to
achieve specimen decision limit levels
bicarbonate will be dissolved in 1.5ml urine for the decision limit sample
level and 6.8mg will be dissolved in 1.5ml for the double the decision limit
sample level. Thus, for 20 specimens, a total of 238mg of sodium bicarbonate
will be used (Table A.3). Each of these specimens will be analysed once.
A.3.6 Test schedule
The tests will be performed on 3 weekends. On day one of the first weekend,
8 urine samples of 30ml each will be collected and 1.5ml aliquots will be
used to measure tCO2 immediately on the Beckman-Coulter DxC R©. Thus 8
tests will be run on that day. One ml will be stored and subsequently pooled
with the other patient specimens. The remaining urine will be stored as 3
aliquots of 7.5ml each and one aliquot of 1.5ml. Ammonium bicarbonate
and sodium bicarbonate will be added as described in the operating proce-
dure above and an additional 48 tests will be run on the spiked samples (24
for sodium bicarbonate and 24 for ammonium bicarbonate). Furthermore, 48
tests will be performed at 2h (corresponding to 24 RT sodium bicarbonate
specimens and 24 at 4◦C). Thus a total of 104 tests will be performed on day
one. On day two, the 1 day old specimens will be run at the 2 temperatures
and will correspond to 48 tests. Thus 152 tests will be performed on the
first weekend. The same procedure will be repeated on the second weekend
with the same number of samples except that (in accordance with Table A.1)
the last patient specimen will not be analysed at the double decision limit
sample level (Table A.4).
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Day Immediate 2 h 24 h Total
unspiked spiked RT 4◦C RT 4◦C
1st Sat 8 24 NH4HCO3 24 24
24 NaHCO3 104
1st Sun 24 24 48
2nd Sat 8 23 NH4HCO3 23 23
23 NaHCO3 100
2nd Sun 23 23 46
3rd Sat 4 8 NH4HCO3 8 8
8 NaHCO3 36
3rd Sun 8 8 16
Other 60
Totals 20 110 55 55 55 55 410
Table A.4: Table of tests conducted stratified by day and time
of day: – Sat: Saturday, Sun: Sunday, RT: room temperature, Other: Limit of
detection experiment
On the third weekend, the same tests as above will be performed but on 4
patient samples and none of these will have the double decision limit sample
level. Thus 52 tests (36 on day one and 16 on day two) will be performed.
The combined 20 samples that have been pooled will be analysed 60 times
on the third weekend. Thus in total 410 tests will have been performed.
When considering the combined results (treating all the weekends as one),
on the first day, 20 urine samples of 30ml each will be collected. Aliquots of
1.5ml will be used to measure tCO2 immediately on the Beckman-Coulter
DxC R© analyser. One ml of urine from each sample will be pooled imme-
diately. Sixty 1.5ml aliquots of the pooled sample will then be measured.
Thus initially a total of 80 tests will be analysed.
On the first day the remaining urine will be stored as 3 aliquots of 7.5ml
each and 1 aliquot of 1.5ml. Ammonium bicarbonate and sodium bicarbon-
ate will be added as described in the operating procedure. An additional 110
tests will be run immediately after adding the appropriate bicarbonate.
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A total of 110 aliquots will be stored in microcentrifuge tubes at 4 oC
and 110 aliquots will be stored at RT. At 2h, the bicarbonate of the 110
aliquots will be analysed. Thus on day one, 300 tests will be processed – 190
tests will be performed immediately and 110 at 2h. On day 2, the remaining
110 samples will be processed. Thirty samples can be processed in 1h and
samples will be analysed in the same order as at time 0.
In the event that the LoD and LoB cannot be determined because the in-
strument cannot read to 0 analyte concentration, the 60 samples that would
have determined the standard deviation near 0 will not be tested. Instead,
the double decision limit sample level will be calculated on all 20 patient sam-
ples such that Table A.1 is modified to an alternate protocol (Table A.5).
Fraction of bicarbonate decision limit 0 0.5 1.0 2.0
Number of specimens in each sample 20 20 20 20
Table A.5: Alternative protocol of number of specimens tested,
initially, for bicarbonate concentration – stratified by factor
of decision limit
Consequently, the tests performed will be changed such the original pro-
tocol (Table A.4) is modified to alternative protocol (Table A.6).
Day Immediate 2 h 24 h Total
unspiked spiked RT 4◦C RT 4◦C
1st Sat 8 24 NH4HCO3 24 24
24 NaHCO3 104
1st Sun 24 24 48
2nd Sat 8 24 NH4HCO3 24 24
24 NaHCO3 104
2nd Sun 24 24 48
3rd Sat 4 12 NH4HCO3 12 12
12 NaHCO3 52
3rd Sun 12 12 24
Totals 20 120 60 60 60 60 380
Table A.6: Alternate table of tests conducted stratified by day
and time of day: – Sat: Saturday, Sun: Sunday RT: room temperature
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A.3.7 Project summary
Twenty 30ml mid-stream urine patient samples from adults are to be used.
A total of 410 total carbon dioxide tests are to be performed to establish
the analytical performance of the method where the analytical performance
is defined by the CV, LoB, LoD, the functional sensitivity and interference.
Stability is the sample property to be determined and the reference range is
the population property to be determined.
The data collected will also be used to determine the analytical feasibil-
ity of using analytical grade (commercially available) ammonium bicarbonate
and sodium bicarbonate as EQA material. The net result will allow the test
to be performed by the laboratory to diagnose RTA. This will complete the
experimental component of the dissertation.
The remainder of the dissertation will be devoted to the design (logistics)
and costing of an EQA program for tertiary hospitals of the Western Cape.
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The objective of the literature review can broadly be divided into three cat-
egories: defining renal tubular acidosis (RTA), identifying an at-risk popula-
tion, and laboratory investigations to diagnose and classify RTA.
It will be shown that the determination of the fractional excretion of bi-
carbonate and therefore the measurement of urinary bicarbonate is essential
for the classification of RTA.
The current clinical acid-base theories will briefly be introduced to ex-
plain why the bicarbonate compound used for the EQA program may affect
the recovery of HCO−3 . It is the potential discrepancy in bicarbonate re-
covery that is the motivation behind the comparison between Na2HCO3
and NH4HCO3 that will be evaluated as possible substrates for the EQA
program.
B.2 Search strategy and quality criteria
The keywords "renal tubular acidosis" were paired with either "interlabora-
tory comparison", "proficiency test", "acid-base", "classify", "epidemiology",
"failure to thrive", "stones" or "quality control" to identify 841 research or
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review articles in the Pubmed database.
B.3 Renal tubular acidosis
B.3.1 Introduction
Renal tubular acidosis is defined, phenomenologically, as persistent hyper-
chloraemic metabolic (low bicarbonate) acidosis with inappropriately alka-
line urine due to inability of the kidney to secrete acid (out of proportion to
any loss of glomerular filtration rate, should such a loss exist)[1, 2].
In 1935 the first description, consistent with the above definition, reports
6 cases (from a cohort of 850 autopsies) of children with FTT and renal
calculi all dying between the ages of 5 and 11 months [3, 4]. Importantly,
the description did not include a normal anion gap metabolic acidosis with
failure of urine acidification. Independently, in 1936, a syndrome of per-
sistent hyperchloraemic acidosis (without excessive diarrhoea or vomiting),
not responding to fluid therapy, associated with renal calculi and FTT was
described[5]. RTA in adults was described[6] followed by an explanation
of (and recognition of the association between) the triad of metabolic aci-
dosis, inappropriately alkaline urine and nephrocalcinosis/nephrolithiasis in
1946[7–9]. The term RTA was introduced in 1951[8, 10].
The complexity and confusion of classification of RTA will be demon-
strated under Section B.3.2. This dissertation proposes that the origin of the
confusion is the attempt to establish a classification based on pathology as is
conventional. This review will construct a classification based on clinical pre-
sentation and investigation which should be less confusing. Then pathologies
will be associated with the subcategories of classification.
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B.3.2 Historical taxonomy
The classification of RTA has changed with time. Initially RTA was classified
as primary or secondary[11] – the former an isolated defect in renal tubular
acidification and the latter associated with additional pathology. Further-
more, primary RTA was considered to be due only to failure to secrete H+
appropriately[12, 13] whereas secondary RTA could be due to insufficient
HCO−3 reabsorption[14]. The publication of two case reports of primary
RTA due to insufficient renal HCO−3 reabsorption changed the classification
to proximal RTA (with failure to reabsorb HCO−3 ) and distal RTA (with
failure to establish adequate gradients of H+)[14, 15]. Thus the classification
was based on presumed histological/anatomical location of the defect[16, 17].
Concomitantly, RTA was classified as Type I, II and III based on the frac-
tional excretion of HCO−3 vs plasma HCO−3 [18]. It should be recognised
that the latter classification is independent of pathology/histology and conse-
quently the two classification systems are not necessarily interchangeable[18].
Nevertheless, by 1972 convergence/reconciliation of the above classification
systems had been achieved[19–21] and is summarised in Table B.1. Type III
Histological Bicarbonate Synonymous
Classification Classification Terms
Distal RTA Type I Classic RTA, Gradient RTA
Proximal RTA Type II Bicarbonate-wasting RTA, Rate RTA
Type III Dislocation RTA
Table B.1: Synonymous terms and analogous categories in the
classification of RTA in 1972 – RTA: renal tubular acidosis
RTA was considered a hybrid of Types I and II[21].
By 1982 the Type III classification (urine biochemistry with features of
Type I and II) had been abandoned as being either transient or not a distinct
entity from Types I or II – thereby unifying the classification systems[22, 23].
With the identification of carbonic anhydrase Type II (CAII) deficiency as a
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distinct/primary RTA manifesting with biochemical features of Types I and
II, the classification Type III RTA was re-introduced[24–26].
By 1997, Type IV RTA was broadly recognised[22, 27, 28] as a sepa-
rate primary RTA due to hypoaldosteronism or pseudohypoaldosteronism
(PHA). Thus, the four broad categories of RTA are summarised in Table
B.2[26, 29]. The minimal investigations to distinguish between them are:
urine pH, fractional excretion of bicarbonate(FeHCO−3 ) after bicarbonate
loading and serum potassium as indicated (Table B.2). Type II (in italics in
Table B.2) is considered the only example of proximal RTA.
Investigation Type I Type II
Urine pH ≥ 5.5 < 5.5
FeHCO−3 < 5% 10− 15%
Serum K+ ↓/N/↑ ↓/N
Type III Type IV
Urine pH ≥ 5.5 < 5.5
FeHCO−3 5− 15% 5− 10%
Serum K+ ↓/N ↑
Table B.2: Classification of RTA in 2002 and basic urine and
serum investigations for diagnosis – derived from [26], RTA: renal tubu-
lar acidosis, FeHCO−3 ; fractional excretion of bicarbonate
Type III has been defined as all forms of RTA with biochemical features
of both Type I and II[1, 30] or as only CAII deficiency[26, 31]. Viewing the
classification from an alternate direction, CAII deficiency has been classified
as Type I[17, 32, 33], Type II[8, 34], omitted from classification[30, 35], as
Type III (a subgroup of Type I[26]) or Type III (distinct from Type I)[31, 36].
Furthermore, for completeness, each of the 4 categories of RTA can be
subdivided aetiologically into primary and secondary. Type I can be com-
plete (normal anion gap metabolic acidosis) or incomplete (no acidosis and
normal serum bicarbonate), depending on whether dynamic function tests
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(DFTT) are required to demonstrate RTA[32], and primary Type II can be
isolated (no aminoaciduria) or associated with Fanconi syndrome[30] (a gen-
eralised aminoaciduria). If hereditary, RTA can be autosomal recessive or
dominant[17, 30, 36, 37]. These subcategories and investigations are dis-
cussed in Sections B.3.5 and B.3.8.
A basic algorithm (compiled from reported results of investigations[26,
29]) for distinguishing between the general categories of RTA is provided















(U-B pCO2 > 2.6kPa)(U-B pCO2 < 2.6kPa)
K+ ↑ K+ ↓ /N
FeHCO−3 5− 10%
Type IVType II
K+ ↓ /N K+ ↑




pH ≥ 5.5 =⇒ Type I or III pH < 5.5 =⇒ Type II or IV
Figure B.1: Basic algorithm for distinguishing between the cate-
gories of RTA – compiled from [26, 29], RTA: renal tubular acidosis, FeHCO−3 :
fractional excretion of bicarbonate, pCO2: partial pressure of CO2, U-B pCO2:
urine to blood pCO2 gradient
included in the more comprehensive acidosis algorithm (Figure B.7).
B.3.3 Clinical presentation and basic investigation
Clinically, the more common RTA I and II can present as growth retardation,
FTT, polyuria, polydipsia[33] or constipation[34]. Investigation may reveal
a normal anion gap metabolic acidosis, refractory rickets/osteomalacia or
hypokalaemia[26, 29]. The original RTA described is classical/distal/Type I
RTA and the more severe autosomal recessive form is associated with sen-
sorineural deafness and nephrocalcinosis/nephrolithiasis[17].
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A Type III finding on investigation can either be secondary or primary.
All the known secondary, and most of the primary forms, reduce to Type I
or II[23]. The only known primary cause for Type III RTA (that does not
reduce to Type I or II exclusively) is the rare CAII deficiency[26, 38]. Clin-
ically, CAII deficiency is distinct – presenting with conductive deafness[17],
osteopetrosis, cerebral calcification, mental retardation and biochemical fea-
tures of both Type I and II (renal bicarbonate wasting and failure of H+
secretion)[24, 25]. Biochemical Type III in the absence of the clinical man-
ifestations of CAII deficiency will reduce to either Type I or II[23]. Given
that CAII deficiency is biochemically intransient, here only CAII deficiency
will be classified as Type III[26]. Furthermore, given that CAII deficiency is
clinically distinct, Type III will be classified separately[31, 36], as originally
intended[18].
Type I Type II
FTT, growth retardation FTT, growth retardation
refractory rickets/osteomalacia refractory rickets/osteomalacia
autosomal recessive: nephrocalcinosis, secondary: Fanconi syndrome
sensorineural deafness on investigation
Type III Type IV
mental retardation, primary: asymptomatic
conductive deafness, PHA2: hypertension
osteopetrosis, secondary: features of
cerebral primary aetiology eg. ambiguous
calcification genitalia, salt-wasting
Table B.3: Clinical presentations in RTA types – FTT: failure to thrive,
PHA2: pseudohypoaldosteronism type 2
Type IV RTA consists of a heterogenous group of pathologies affecting the
renin-angiotensin-aldosterone axis[28] and the effector renal proteins – min-
eralocorticoid receptor[39] and the epithelial sodium channel (ENaC)[26, 28].
Type IV RTA is usually asymptomatic and incidently identified biochemi-
cally as hyperkalaemic normal anion gap metabolic acidosis[26]. Pseudohy-
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poaldosteronism Type II (PHA2 or Gordan’s syndrome) presents with arte-
rial hypertension[40], hyperkalaemia but normal glomerular filtration rate by
definition[41]. The clinical presentations are summarised in Table B.3.
B.3.4 Epidemiology
Data on the prevalence of RTA in children with FTT or rickets could not be
found. It was reported that 22% (95% confidence interval (CI) 11−36%) of a
cohort of 46 osteoporotic patients had incomplete RTA I when diagnosed by
the NH4Cl DFTT. For the same cohort, 35%(CI 21 − 50%) were identified
as having incomplete RTA by furosemide DFTT[42]. It was also reported
that 20% of a cohort of 300 patients with nephrolithiasis had either inherited
or acquired Type I RTA[1].
B.3.5 Pathology and molecular basis of disease
The histological classification is more convenient than the bicarbonate clas-
sification when considering the pathology. Briefly, in acid-base homeostasis,
the kidney is responsible for reabsorbing filtered bicarbonate and generat-
ing bicarbonate from CO2. The latter is accomplished by buffering secreted
H+ generated from water and CO2 with ammonia and phosphate – allowing
bicarbonate generation.
B.3.5.1 The proximal tubule and primary inherited RTA II
The cells of the proximal convoluted tubule (PCT) are responsible for re-
absorption of bicarbonate[8, 26, 43]. The cell is depicted schematically in
Figure B.2. There is an adenosine triphosphate(ATP) independent mech-
anism of HCO−3 reabsorption which is actuated by a transtubular Na+
gradient (depicted in green) and an ATP dependent HCO−3 reabsorption
mechanism (depicted in blue)[8, 26, 43]. The latter appears to be less signif-
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icant. Regarding the ATP independent mechanism, a luminal membrane
sodium hydrogen exchanger(NHE-3) and a basolateral membrane kidney
sodium bicarbonate co-transporter (kNBC) facilitate the secretion of hy-
drogen and the reabsorption of HCO−3 , respectively, down the sodium con-
centration gradient[1, 26, 33, 34]. The ATP dependent mechanism of reab-
sorption requires a luminal hydrogen pump and a basolateral Na + /K+-
ATPase(adenosine triphophatase)[8, 26, 33, 43]. The sodium bicarbonate
co-transporter (kNBC) is also referred to as anion exchanger 1 (AE1). In
Figure B.2 the proximal tubular cell regulation of ammonia (via facilitated
NH+4 transport through a Na+/K+-antiporter) is depicted[8, 44] in vio-
let. It has also been reported that ammonia (NH3) diffuses directly across
the cell membrane[34, 45] or that the Na+/K+-antiporter facilitates NH+4

























































Figure B.2: Proximal tubular cell H+ regulatory pathways – [8,
44] NHE-3: sodium-hydrogen exchanger-3, CAII: carbonic anhydrase type
II, kNBC: kidney sodium bicarbonate exchanger
3 is responsible for autosomal dominant RTA II[30] but as yet the mutation
28
has not been identified[36]. Autosomal recessive (AR) RTA II with ocular
abnormalities is associated with mental retardation and has a mutation in
SLC4A4 which codes for kNBC[30, 36]. The proximal tubular proteins with
known inherited defects are depicted in red in Figure B.2.
B.3.5.2 The distal tubule, intercalcated cells and primary inher-
ited RTA I
The distal convoluted tubule (DCT) and cortical collecting duct (CCD) con-
sist of at least two types of cell. The principal cells contain the amiloride
sensitive ENaC and the intercalcated cells are responsible for secreting either
H+ (α cells) or HCO−3 (β cells)[8, 26]. The β-intercalcated cells are of op-






















































Figure B.3: Regulation of H+ by the α-intercalcated cell com-
piled from – [8, 26] CAII: carbonic anhydrase II, kAE: kidney anion ex-
changer
for the kidney anion exchanger(kAE) is responsible for autosomal dominant
(AD) RTA I. The known genetic causes for AR RTA I are all mutations in the
H+ATPase. Mutation in ATP6V1B1 which codes for the β1-subunit of the
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H+ATPase[36, 37] produces RTA I with sensorineural deafness, and muta-
tion in ATP6V0A4 which codes for the α4-subunit of the H+ATPase[36, 37]
produces RTA I without hearing loss.
B.3.5.3 The cortical collecting duct, the principal cell and pri-
mary inherited RTA IV
The principal cell contains ENaC and is regulated by aldosterone. The bind-
ing of aldosterone to the mineralocorticoid receptor induces both genomic
and extra-genomic effects. In particular, in the α-intercalcated cell of the
DCT, the upregulation of the apical proton pumps is a non-genomic effect


























Figure B.4: Role of the principal cell in RTA IV – [46] ROMK: renal
outer medullary potassium channel, WNK: with no lysine, ENaC: epithelial
sodium channel
Figure B.4 is a schematic of the principal cell depicting the various PHA
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defects – only the subcellular pathways relevant to the known causes of PHA
are depicted[46]. Briefly, aldosterone diffuses across the cell membrane and
binds to the intracellular mineralocorticoid receptor. One of the reasons for
the mineralocorticoid specificity is the inactivation of cortisol to cortisone by
β hydroxysteroid dehydrogenase 2[47]. The genomic effects include upregula-
tion of ENaC and the basolateral Na+/K+−ATPase. The subcellular signal
WNK1 (with no lysine where K is the symbol for lysine) phosphorylates and
thereby activates ENaC while WNK4 dephosphorylates ENaC. Both WNK1
and WNK4 inhibit the luminal membrane renal outer medullary potassium
channel(ROMK) by interacting with the scaffolding[48]. The principal cell
promotes H+ excretion indirectly by increasing the negative potential differ-
ence of the tubular lumen[8, 26, 29]. A H+/K+−ATPase may also increase
secretion directly but appears to be more important in K+ homeostasis[26].
The primary PHA defects are: AR PHA I with defects in the genes
coding for the ENaC, AD PHA I with defects in the genes coding for the
mineralocorticoid receptor, AD PHA II subtype a associated with a locus
on chromosome 1q31-q42, AD PHA II subtype b due to mutations causing
underexpression of WNK4, AD PHA II subtype c due to mutations caus-
ing overexpression in WNK1, and PHA for which no gene locus has been
identified[46].
B.3.5.4 The loop of Henle and ammonium secretion
The loop of Henle contains the furosemide sensitive sodium-potassium-chloride
symporter which is capable of reabsorbing NH+4 instead of potassium[8, 44].
The reabsorbed NH+4 is the source of the NH3 required for buffering the dis-
tally secreted H+. It is, however, not obvious how NH3 is delivered distally
as opposed to NH+4 [28]. It is also suggested that the NH3 diffuses directly
across the membrane[28, 34, 45]. The two mechanisms (which may not be
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mutually exclusive) for the delivery of ammonia are depicted in Figure B.5.
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Figure B.5: The fate of ammonia and ammonium in the nephron
– modified from [28] PCT: proximal convoluted tubule, DCT: distal convoluted
tubule, CCD: cortical collecting duct
There are at least two theories regarding the role ofNH+4 . The traditional
view is thatNH3 consumes secretedH+ in the distal nephron (formingNH+4 )
and thereby allows regeneration of HCO−3 . The traditional view is depicted
on the left in Figure B.6. The alternate view is that the formation of NH+4
consumes NH3 that would otherwise undergo hepatic carbamylation which,
in turn, consumes HCO−3 [49]. Thus NH+4 conserves HCO−3 – the right side
of Figure B.6.
B.3.5.5 CA II deficiency and RTA III
CA II is present both proximally and distally within the nephron (Figures B.2
and B.3). CA II deficiency has been described in patients on most continents
but the majority of the cases appear to be due to a founder effect in an Arab
tribe that migrated to North Africa[38]. The classification of RTA, with some

















































Figure B.6: Potential mechanisms for the role of NH3 in acid-
base regulation
Type I Type II
secretory insufficient HCO−3 reabsorption
AD RTA I , AR RTA I AD RTA II, AR RTA II with deafness,
voltage dependent AR RTA II without deafness
Type III Type IV
carbonic anhydrase II deficiency hypoaldosteronism
PHA
AD PHA I, AR PHA I,
AD PHA II b, AD PHA II c,
AD PHA II a, PHA III
Table B.4: Classification of RTA and some primary causes
– RTA: renal tubular acidosis, AD: autosomal dominant, AR: autosomal recessive,
PA: pseudohypoaldosteronism
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B.3.6 Pathological basis of classification
The classification system in Table B.2 is based on biochemical investigation
correlated with the distinct clinical findings in Table B.3. This section cor-
relates taxonomy and pathophysiology and should be interpreted together
with Section B.3.5.
Type I RTA is due to impaired H+ secretion with a secondary defect in
NH+4 excretion[8, 26]. The defect in renal collecting duct α-intercalcated
cell H+ secretion can either be direct or indirect where a direct defect is
present in the H+-ATPase on the apical membrane and an indirect defect is
on the basolateral membrane HCO−3 /Cl− exchanger (AE1). Both the direct
and indirect failure to secrete H+ are defined as classical or secretory Type
I RTA[26]. Type I RTA is not known to involve the H+/K+-ATPase, also
present on the α-intercalcated cell, which may explain the possibility of hy-
perkalaemia (Table B.2).
Non-secretory defects manifesting as Type I RTA are either gradient-,
low buffer- or voltage-dependent. Gradient-dependent RTA is defined by a
failure to maintain an H+ gradient (H+-ATPase is intact) due to ‘back-leak’
of H+. Gradient-dependent RTA is often secondary to amphotericin B treat-
ment.
A second non-secretory Type I defect is ‘low buffer’ Type I RTA. The
‘low buffer’ type defect is defined by proximal tubular NH+4 secretion failure
(seen in nephrocalcinosis and chronic interstitial nephritis)[26].
The H+-ATPase of secretory Type I RTA is also influenced by the elec-
trochemical gradient across the cell membrane – which is maintained by the
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principal cells. It is necessary for H+ to be secreted along the distal lumen
electronegative transepithelial gradient. A defect in this transepithelial elec-
trogradient is a voltage-dependent defect and is due to impaired Na+ trans-
port – secondary to obstructive uropathy, salt-losing congenital adrenal hy-
perplasia(CAH), administration of drugs (lithium, amiloride, trimethoprim,
pentamidine). Presumably the consequent impairment in K+ transport ac-
counts for the hyperkalaemia of voltage-dependent Type I RTA.
Type I Type II
Secretory
classical RTA
apical H+-ATPase impaired proximal tubular










principal cell Na+ Type IV
transport defect
with secondary K+ Hyperkalaemic Type 4
transport derangement impaired ammoniagenesis
Type III due to hyperkalaemia
impaired bicarbonate
CA II deficiency reabsorption (> I, < II)
Table B.5: Taxonomy-pathophysiology correlation in RTA – com-
piled from [26]. AE1: anion exchanger 1, CA II: carbonic anhydrase II, ATPase:
adenosine triphosphatase
RTA II is secondary to impaired HCO−3 reabsorption while RTA III is a
CA II deficiency
RTA IV is associated with hypoaldosteronism and PHA. Although the
distal tubular cells have H+/K+-ATPase, these are primarily responsible for
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K+ reabsorption rather than H+ excretion – thus the impaired H+ secretion
is not the cause of the acidosis. Rather, hyperkalaemia inhibits ammonia
reabsorption at the ascending limb of the loop of Henle[28]. The acidosis is
due to impaired proximal tubular NH+4 secretion – which buffers the secreted
H+. There is a consequent HCO−3 reabsorption defect which is intermedi-
ate between RTA I and RTA II. Thus RTA IV is due to hyperkalaemia.
Thus, other than the defects in the renin-angiotensin-aldosterone axis, any
cause of hyperkalaemia will result in RTA IV[26] such as chronic renal fail-
ure, potassium-sparing diuretics, heparin, insulin antagonists, β-adrenergic
antagonists, α-adrenegic agonists, digitalis, succinylcholine. Thus in RTA
IV, hyperkalaemia is causal whereas in voltage dependent Type I RTA, hy-
perkalaemia is a consequence.
The taxonomy-pathophysiology correlation is summarised in Table B.5.
B.3.7 Diagnostic algorithms
The biochemical results of the basic algorithm for RTA diagnosis (Figure B.1)
are summarised in Table B.2 and these features are common to all presen-
tations. The pathology should enter the differential diagnosis of a metabolic
acidosis and should be isolated (or recognised as distinct) based on the serum
anion gap (SAG)[33, 50] and the urine anion gap (UAG)[8, 33, 34, 51] or urine
osmolar gap (UOG)[8, 51] in the acidosis algorithm (Figure B.7). An IgG
paraprotein can induce either a low normal or negative SAG and RTA[50].
In neonates, UAG should be replaced with a DFTT[34] because ammonium
generation matures postnatally.
Urine pH and Fe(HCO−3 ) distinguish hyperkalaemic RTA Type I from






















eGFR > 20ml/min eGFR < 20ml/min
> 16mmol/L < 16mmol/L
UAG ≤ 0mmol/L UAG > 0mmol/L
< 5% > 5%
UOG ≤ 100mOsm/kg UOG > 100mOsm/kg
Figure B.7: Diagnostic algorithm for confirming RTA in
metabolic acidosis – [33, 50] SAG: serum anion gap, eGFR: estimated
glomerular filtration rate, UAG: urine anion gap, UOG: urine osmolar gap,
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pH < 5.5 pH > 5.5
pH ≥ 5.5 =⇒ Type I or III pH < 5.5 =⇒ Type II or IV
Figure B.8: Hyperkalaemic RTA diagnostic algorithm – only in-
creased K+ emphasized – [26, 29] RTA: renal tubular acidosis, FeHCO−3 :
fractional excretion of bicarbonate, pCO2: partial pressure of CO2, U-B pCO2:
urine to blood pCO2 gradient
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perkalaemic RTA Type I[52]. Furosemide or NH4Cl should stimulate the
renin-angiotensin-aldosterone system in Type IV RTA – manifesting as a re-
duction in urine pH and urine [K+] ([K+]u). Conversely, in the presence
of RTA and the furosemide/NH4Cl test, failure to reduce pH and [K+]u
implies hyperkalaemic Type I RTA[26]. The refined algorithm for hyper-









Figure B.9: RTA IV diagnostic algorithm[8]
RTA IV is due to hyperkalaemia. Primary causes of the hyperkalaemia
include hypoaldosteronism and PHA. The direct method for distinguishing
between them is aldosterone measurement[8]. A proxy measure of aldosterone
activity is transtubular potassium gradient (TTKG)[26, 28]. The direct mea-
sure of aldosterone is preferred[53]. The algorithm to follow once RTA IV
has been diagnosed is depicted in Figure B.9.
The definitive investigations for diagnosis are presented in Section B.3.8.
A prominent feature of classical/secretory Type I RTA is nephrolithiasis and
an algorithm has been compiled from reported data[54](Figure B.10).
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Figure B.10: Diagnostic algorithm for renal stones – compiled from
[54] PTH: parathyroid hormone, Ca: calcium
B.3.8 Laboratory investigation
The laboratory diagnosis can be divided into three categories: diagnosing
complete RTA and categorising the RTA, distinguishing between the subcat-
egories of RTA, and DFTT to diagnose incomplete RTA. The molecular basis
of the genetic RTAs is discussed in Section B.3.5 but the molecular diagnosis
is not addressed in this review.
Arterial blood gas and serum Na+, K+, Cl−, HCO−3 analysis are used
to determine whether a normal anion gap metabolic acidosis exists (Figure
B.7). Once a hyperchloraemic metabolic acidosis is confirmed, urine and
serum bicarbonate and creatinine, and urine pH, are determined to exclude
diarrhoea as the cause of hyperchloraemic metabolic acidosis and to confirm
the diagnosis of RTA (Figure B.7).
Sodium bicarbonate is administered to correct the serum bicarbonate be-
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fore determining the Fe(HCO−3 ) and thereby classifying the RTA (Figure
B.1).
There are various DFTTs to diagnose incomplete RTA[8]. However, since
there is no clinical management for this condition, it is debatable whether
they are of clinical utility. The bicarbonate loading test is the definitive test
for RTA II[8]. DFTT (furosemide or NH4Cl stimulation tests) are, however,
useful at detecting a hyperkalaemic RTA I being masked by RTA IV.
The furosemide stimulation test inhibits the reabsorption of K+ by the
Na+/K+/2Cl− co-transport system – increasing the distal Na+ delivery[8,
26] and luminal electronegativity[26, 33]. The normal response is for the urine
pH to decrease and K+ excretion to increase – neither of these events occurs
in voltage-dependent RTA I[8, 26, 33]. A urine pH > 5.5 after furosemide
stimulation indicates hyperkalaemic RTA I. The furosemide can be delivered
orally (40mg)[8] or intravenously (1mg/kg body weight)[26]. The urine pH
should be measured half-hourly for up to 5h, for the orally administered test,
(or up to 3h for the intravenous test) to determine the lowest pH. A pH <
5.5 is a normal response. The pH does not reduce to 5.5 in hyperkalaemic
RTA. The NH4Cl test is the definitive method for RTA I but NH4Cl is
unpalatable and requires an anti-emetic[8].
B.4 The physicochemical acid-base theory, RTA
and bicarbonate proficiency testing
An introduction to clinical chemistry acid-base theories is provided in Ap-
pendix D1. Two theories dominate – bicarbonate-centric Henderson-Hasselbalch
based approaches and the physicochemical approach by Stewart. Evidence
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suggests that the only real difference between the two is that the latter con-
siders the effect of non-bicarbonate buffers. Nevertheless, the effect appears
to be sufficiently small so as not to make a difference to clinical decisions.
Bicarbonate based approaches measure bicarbonate indirectly from pH
and pCO2 in an in vitro environment. The approach has been criticised for
not reflecting the in vivo environment[55, 56]. The interpretation of Stew-
art’s approach suggests that bicarbonate is a dependent factor with regard to
acid-base homeostasis and that consequently bicarbonate is a function of the
difference between serum cations and anions – the strong ion difference(SID).
Traditional models of RTA emphasize the role of H+-pumps and trans-
porters and HCO−3 transporters but, as has recently been published, these
pumps and transporters rely on cations (like Na+) and anions (like Cl−) to
maintain electroneutrality and consequently do not refute Stewart’s theory[31].
Thus, the compound selected for a potential proficiency testing program
should not violate either theory. Sodium bicarbonate is a potential compound
but affects SID in the physicochemical approach. Ammonium bicarbonate
should in principle have the same effect in both theories.
B.5 Further research required
Additional genetic causes for RTA need to be determined. Although the
mechanisms of the effect of transporters have been described, the regula-
tion of these transporters remains to be determined. Without these regula-
tory mechanism data, neither the physicochemical acid-base theory nor the
bicarbonate-centric theory can be disproved[31]. Elucidation of the regula-
tory mechanisms may refute at least one theory.
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A proficiency testing program does not exist for urinary bicarbonate.
Such a program would facilitate multicenter trials, allow comparison of labo-
ratory results and allow epidemiological studies on the prevalence of RTA in
various groups. The existence of proficiency testing programs would also al-
low the determination of the clinical sensitivity, specificity, and positive and
negative predictive values of employing the diagnostic algorithms (Figure
B.7).
B.6 Summary
RTA is a well described pathology but there is little epidemiological informa-
tion on this condition. Many molecular causes have been elucidated. How-
ever, the regulation of the pathways has as yet not been clearly described.
The study of the regulation of the molecular mechanisms of RTA may pro-
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Urine bicarbonate analysis is required in the diagnostic workup of renal tubu-
lar acidosis (RTA) – which should be considered in wasted, stunted children.
The expected incidence of stunting, in South Africa, is 250 000 per annum –
establishing a need for urine bicarbonate testing. For accreditation, a labora-
tory requires external quality assurance for urine bicarbonate. The absence
of proficiency testing for urine bicarbonate poses a problem.
Accreditation requires at least an interlaboratory comparison (ILC) pro-
gram. Bicarbonate volatility hinders ILC. Here an ILC is designed based on
the recovery of bicarbonate from freshly spiked urine samples.
The analytical performance of the Beckman-Coulter DxC R© assay for total
bicarbonate in urine is calculated and used to determine acceptable limits of
an ILC. Sodium bicarbonate is selected as ILC substrate as a safer, cheaper
and more soluble option than ammonium bicarbonate. This work is a case
study in proficiency testing of unstable analytes.
The ILC uses difference in recovery of exogenous bicarbonate (to negate
variation in endogenous bicarbonate) to compare laboratories. The results
are analysed using standard deviation index plots and Youden plots.
The marginal administrative cost of the ILC is R4, 64 per ILC cycle. The
marginal costs of analyses are R4, 64 on an arterial blood gas analyser and
R17, 64 on the Beckman-Coulter DxC R©.
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C.2 Introduction
Renal tubular acidosis (RTA) is defined phenomenologically as persistent
hyperchloraemic metabolic (low bicarbonate) acidosis with inappropriately
alkaline urine due to inability of the kidney to secrete acid (out of proportion
to drop in glomerular filtration rate – should such a drop exist)[1, 2]. The
measurement of urine bicarbonate is required for the classification of RTA[3]
Clinical laboratories are accredited by authoritative peer-review bodies[4–
6]. Several such authoritative bodies exist – accrediting by variable criteria[4–
10]. Generally, medical laboratories endeavour to be accredited to ISO 15189
standards[5] and this allows the laboratory to select the tests to be evaluated
and the scope of the evaluation. The National Health Laboratory Service
in South Africa is accredited by the South African National Accreditation
Service[6] and attempts to have all its tests accredited – the individual tests
are listed on the accreditation certificate[11].
A requirement for test accreditation is that the laboratory should sub-
scribe to a proficiency testing (PT) program[5, 6] for that test. No such
program was identified for urine bicarbonate. ISO 15189 does allow for inter-
laboratory comparison (ILC) - should PT be unavailable[5]. This dissertation
designs an ILC program[5] (based on recovery experiments and a Clinical and
Laboratory Standards Institute (CLSI) guideline[12]) for urine bicarbonate –
allowing accreditation. Recovery is selected to avoid the problem of volatility.
The factors to be considered when selecting a bicarbonate compound are
whether the compound violates relevant acid-base theories, stability, repro-
ducibility of results, cost and ease of handling – solubility and safety. Two
acid-base theories dominate in clinical medicine. The traditional Henderson-
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Hasselbalch theory is the more widely used while the new physicochemi-
cal theory is favoured by anaesthetists and intensivists. The Henderson-
Hasselbalch approach is bicarbonate-centric and, in principle, should not
be affected by the bicarbonate compound selected[13]. The physicochemi-
cal model focuses on the strong ion difference (SID) in its interpretation of
acid-base disturbances[14]. In the physicochemical approach only predefined
cations are considered. Thus, depending on the cation in the compound
spiked, the SID may be significantly changed. The compounds to be eval-
uated for the recovery experiments are ammonium bicarbonate (acceptable
in both theories) and sodium bicarbonate (sodium, as a strong ion, should
induce alkalosis in the physicochemical approach).
C.3 Materials and methods
Bicarbonate was measured as total CO2 (the sum of all bicarbonate species)
by a pCO2 electrode on a Beckman-Coulter DxC R© analyser. All bicarbonate
species are converted to CO2 by acidification (Figure C.1):
x1CO2 + x2H2CO3 + x3HCO−3 + x4CO2−3 + (x3 + 2x4)H+ EGGGGGCAcid
(x1 + x2 + x3 + x4)CO2 + (x2 + x3 + x4)H2O.
Total carbon dioxide (tCO2) (on the DxC platform) has an analytical range










Figure C.1: The effect of acidification on bicarbonate species
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the total imprecision is 2.8% at 28.99mmol/L. The resultant CO2 is mea-
sured using a CO2 ion selective electrode (ISE)[15].
The Bayer RapidLab R© 348 blood gas analyser uses a pH ISE to calculate
the hydrogen ion concentration directly and a pCO2 ISE to calculate the
actual HCO−3 [16] by re-arranging the Henderson-Hasselbalch equation such
that
HCO−3 act = 0.031× pCO2 × 10(pH−6.1). (C-1)
The total CO2 can then be calculated as
tCO2 = 0.031pCO2 +HCO−3 act. (C-2)
Analytical grade ammonium bicarbonate (11213-1KG-R) and analytical grade
sodium bicarbonate (13433-1KG-R) were purchased from Sigma-Aldrich R©.
Urine was not collected under mineral oil[17]. Twenty 1.5ml aliquots of
urine from 20 individuals (1 aliquot from each of the patient samples were
tested for tCO2 immediately and immediately after spiking with a bicarbon-
ate compound. From each of the 20 individuals, 18 additional aliquots (from
the original patient sample) of 1.5ml were collected. Of the 18 aliquots, 3 sets
(or samples) of 5 specimens were spiked with 1.6mg (13.5mmol/L), 3.2mg
(27mmol/L) or 6.4mg (54mmol/L) of NH4HCO3, respectively. Of the re-
maining 3 urine aliquots, each aliquot was spiked with 1.7mg (13.5mmol/L),
3.4mg (27mmol/L) or 6.8mg (54mmol/L) of NaHCO3. The aliquots
spiked with NaHCO3 were analysed immediately – for comparison with
NH4HCO3 aliquots that were analysed immediately. One of the NH4HCO3
quintuplicates was analysed for tCO2 immediately, 2 were stored at room
temperature and analysed at 2h and at 24h. The remaining 2 NH4HCO3
quintuplicates were stored on ice and refrigerated at 4oC before being anal-
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ysed at 2h and 24h. One urine sample was spiked with NH4HCO3 (as de-
scribed above) and aliquots (forming the quintuplicate) were acquired from


















Figure C.2: The aliquots of the original urine patient sample
required for spiking – stratified by compound, concentration, storage time
and storage temperature, RT: room temperature
are reported as zero. Specimens with bicarbonate readings greater than
50mmol/L were diluted 1:2 and re-analysed.
The results were used to determine the HCO−3 stability in the sealed
microcentrifuge tube, the precision of the instrument, the functional sensi-
tivityof the assay, a reference range, and to compare the results for NaHCO3,
NH4HCO3 and the gravimetrically prepared HCO−3 . The 24h NH4HCO3
samples were also analysed on a Bayer Healthcare R© Rapidlab 348 arterial
blood gas (ABG) analyser.
Normal distributions were excluded using the Shapiro-Wilk test and QQ-
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plots. Statistically significant differences were evaluated using either the
paired student t-test or analysis of variance (ANOVA) if the sample analyte
results were parametrically distributed or by the Wilcoxon test or Mann-
Whitney U test if non-parametrically distributed. The effect of the sta-
tistically significant difference (also referred to as significant difference) is
evaluated by at least one of 4 criteria. These criteria can be subjective where
either the effect on clinical outcome is considered or the degree of overlap of
the boxplots is compared or it can be objective by comparing the statistically
significant difference to the analyser imprecision or the relative change values
for the analyte.
C.4 Results
The results are divided into:
1. comparison of different bicarbonate compounds
2. stability
3. comparison of DxC total carbon dioxide (tCO2) with blood gas analysis
4. reference range
5. functional sensitivity.
All the results are the difference between the measured tCO2 of the subject’s
spiked specimen and the subject’s native (unspiked) specimen.
C.4.1 Comparison between sodium bicarbonate and
ammonium bicarbonate
The tCO2 of the spiked samples analysed initially (t = 0) are depicted in
Figure C.3 where the predicted bicarbonate concentrations are on the x-axis,
the bicarbonate recovered is on the y-axis and each of the box-and-whisker
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plots represents either a NH4HCO3 sample or a NaHCO3 sample as stated
along the x-axis. The description of the raw data (Table S-1) and the infer-




































n =20 n =20 n =20 n =20 n =20 n =20
13.5 mmol/L 27 mmol/L 54 mmol/L
Figure C.3: Recovery (immediately after spiking) of bicarbonate
added to urine specimens
The results in Figure C.3 were combined by solution type (NH4HCO3 vs
NaHCO3) and plotted as a recovery ratio in Figure C.4. The paired student
t-test was used to show a statistically significant difference (p = 7.8× 10−6)
between the mean recovery ratio of NH4HCO3 and NaHCO3. The recovery
of the central 90% of NH4HCO3 is in the range 60 − 91%. For NaHCO3
the central 90% recovery is in the range 64− 103%. Ammonium bicarbonate
read 7.5% less (95%CI = 4.4− 10%).
Bicarbonate recovery was not significantly different between NH4CO3




























n = 60 n = 60
Figure C.4: Recovery ratio of bicarbonate by solution type
(analysis performed immediately post spiking)
the NaHCO3 variability appears to be less than that of the NH4CO3 sample.
The dissolution process was much longer for ammonium bicarbonate and this
may account for the variability. The sodium bicarbonate variability of the
54mmol/L sample was greater than that of the corresponding ammonium
bicarbonate sample. This is likely to be due to the dilution of the sodium
bicarbonate solution to measure tCO2, since it exceeded the upper limit of
the measuring range. Furthermore, the sodium bicarbonate solution gener-
ally reads a higher tCO2 than ammonium bicarbonate. Both ammonium
bicarbonate and sodium bicarbonate recoveries were considerably lower than
the expected 100% (Figure C.4).
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C.4.2 Stability experiments
For the NH4HCO3 sample, the effect of temperature at 2h (Figure C.5) and
24h (Figure C.6) is shown, where each concentration is stratified into initial






Effect of storage temperature on 2 hour samples

















Initial Room 4 Initial Room 4 Initial Room 4
n =20 n =19 n =20
13.5 mmol/L 27 mmol/L 54 mmol/L
Figure C.5: Effect of temperature on the stability of ammonium
bicarbonate after 2 hours for the 3 decision levels – n: count,
room: room temperature, initial: at t = 0
No difference exists in measurement whether the analyte is stored at room
temperature or at 4oC (Figures C.5 and C.6). The effect of storage time on
the NH4HCO3 room temperature specimens (Figure C.7) and on the refrig-
erated specimens (Figure C.8) is shown. Regarding the effect of storage
time on recovery, a significant difference is not evident. However, there is







Effect of storage temperature on 24 hour samples

















Initial Room 4 Initial Room 4 Initial Room 4
n =20 n =19 n =20
13.5 mmol/L 27 mmol/L 54 mmol/L
Figure C.6: Effect of temperature on the stability of ammonium
bicarbonate after 24 hours for the 3 decision levels– n: count,






Effect of storage time on room temperature samples

















Initial 2 24 Initial 2 24 Initial 2 24
n =20 n =19 n =20
13.5 mmol/L 27 mmol/L 54 mmol/L
Figure C.7: Effect of storage time on the stability of ammonium
bicarbonate stored at room temperature for the 3 decision







Effect of storage time on refrigerated samples

















Initial 2 24 Initial 2 24 Initial 2 24
n =20 n =19 n =20
13.5 mmol/L 27 mmol/L 54 mmol/L
Figure C.8: Effect of storage time on the stability of refriger-
ated ammonium bicarbonate for the 3 decision levels refrigeration
temperature: 4◦C, n: count, initial: at t = 0
The descriptive and inferential statistics for the effect of storage temper-
ature and storage time confirm the above observations and is presented in
the supplemental data (Table S-3 and Table S-4, respectively).
C.4.3 Blood gas analysis comparison
The majority of these tests will be conducted in peripheral laboratories which
may not have an automated analyser for the measurement of tCO2 but
may have a point-of-care arterial blood gas analyser (ABG). Thus, the 24h
NH4HCO3 specimens were analysed on both the DxC and ABG analysers
(Figure C.9). ABG tCO2 rather than HCO3 was compared to DxC tCO2
because, from Equation (C-2), the former is the equivalent to the DxC tCO2.
The recoveries on the DxC and ABG analysers are comparable (Figure













ABG vs DxC bicarbonate recovery












DxC ABG DxC ABG DxC ABG
n = 40 n = 40 n = 40
13.5 mmol/L 27 mmol/L 54 mmol/L
Figure C.9: 24 hour ammonium bicarbonate recovery on the DxC
and ABG analysers – ABG: Bayer RapidLab R© 348 blood gas analyser, DxC:
Beckman-Coulter DxC R©, n: count
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nificant differences between the ABG and DxC measurements but the con-
tribution of these differences are not significant (Supplemntal Tables S-5 and
S-6). The variability in recovery reduces with increasing spiked concentra-
tion – the 54mmol/L ammonium bicarbonate solution was rarely analysed
in dilution (Figure C.9). This can be accounted for both by the increased
variability in the measurement of the lower masses and the relatively greater
contribution of innate urinary bicarbonate (that was below the limit of de-
tection (LoD) of 5mmol/L) at the lowest bicarbonate level.
C.4.4 Functional sensitivity
The functional sensitivity was interpolated by using the method of least
squares to fit a power function (y = axb + c) to the precision data for the
initial ammonium bicarbonate measurements. The power function was se-
lected because it approaches an asymptote at infinity and approaches infinity
at zero – analagous to the functional sensitivity. The coefficient of variation
(CV) and standard deviation (SD) were calculated from the measured bicar-
bonate (Table C.1).
Ammonium bicarbonate Sodium bicarbonate
mmol/L mmol/L
Expect n µ SD CV (%) µ SD CV (%)
13.5 20 10.1 1.88 18.6 11.2 1.87 16.6
27 20 20.0 2.87 14.3 23.0 3.94 17.0
54 20 41.7 4.09 9.81 43.4 5.93 13.7
Table C.1: Intra-assay precision data for bicarbonate: Compar-
ison between NaHCO3 and NH4HCO3 – n: count, SD: standard devi-
ation, CV: coefficient of variation, Expect: expeected bicarbonate concentration
(mmol/L), µ : mean
Equation (C-3) is the formula relating CV to the mean of the measured
bicarbonate. Consequently, the CV for urinary bicarbonate (as a function of
63
measured bicarbonate) is
CV (%) = 54〈NH4HCO3〉−0.453, R2 = 0.99 (C-3)
where 〈NH4HCO3〉 is the mean of the measured bicarbonate whenNH4HCO3
is added. Consequently, the functional sensitivity is 8.95mmol/L. The for-
mula for the CV based on expected bicarbonate is given by
CV (%) = 63.4 (E(NH4HCO3))−0.463 , R2 = 0.99 (C-4)
where E(NH4HCO3) is the expected bicarbonate when NH4HCO3 is added.
The functional sensitivity for the expected bicarbonate is 12mmol/L.
Similarly, the CV based on the measured bicarbonate when using sodium
bicarbonate is
CV (%) = 24.4〈NaHCO3〉−0.142, R2 = 0.62 (C-5)
where 〈NaHCO3〉 is the mean of the measured bicarbonate whenNaHCO3 is
added. Consequently, the functional sensitivity is 4.1mmol/L. The formula
for the functional sensitivity based on expected bicarbonate is given by
CV (%) = 25.2 (E(NaHCO3))−0.143 , R2 = 0.66 (C-6)
where E(NaHCO3) is the expected bicarbonate when NaHCO3 is added.
The functional sensitivity for the expected bicarbonate is 5.0mmol/L, and
lower values should be reported as < 5mmol/L.
64
C.4.5 Recovery difference experiments
The predicted SD for the difference between the 27mmol/L and 13.5mmol/L
ammonium bicarbonate standards is 3.43mmol/L (Table C.1). The pre-
dicted CV (based on the mean of the differences) is 34.5%. Similarly the
predicted SD for the difference between the 54mmol/L and 13.5mmol/L
ammonium bicarbonate standards is 4.5mmol/L, with a CV of 14.2%[18].
The measured CV of the difference between the 27mmol/L and 13.5mmol/L
standards for ammonium bicarbonate is 16%. The measured CV for the dif-
ference between the 54mmol/L and the 13.5mmol/L standards for ammo-



























































Figure C.10: The measurement of difference in recovery: the mea-
surements are performed in duplicate – first on sample 1 then on sample 2. Sx
specimen number x in sample 1 where x = 1, x = 2 and x = 3 represent the high,
middle and low controls, respectively. S′x specimen number x in sample 2
The reduction in variability when measuring the difference in bicarbon-
ate standards as compared to predicted variability (Section C.4.5) supports
the conclusion that it is the innate, unmeasured urinary bicarbonate that in-
creases the variability. By measuring the difference in recovery (Figure C.10),
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the uncertainty associated with the unmeasured, innate urinary bicarbonate
is eliminated (Supplemental data S-1).
C.4.6 Reference range
Twenty-five specimens were analysed after adjusting the DxC analyser to
report results greater than 3mmol/L – allowing results below the LoD (of
5mmol/L) to be reported. Reporting results below the LoD is unacceptable
for a single result, but can be performed for a sample consisting of several
specimens. Of the 25 results, 12 were < 3mmol/L and 13 were recordable
(≥ 3mmol/L). Thus the median (M) result is 3mmol/L. Twelve of the
results were mirrored (thus a symmetric distribution is assumed) about M
thus accounting for the 12 unmeasurable specimens. Furthermore, given the
imposed symmetry, the mean (µ) equals M . Of the resultant 25 results, 2
were rejected as outliers – the highest urine bicarbonate produced a negative
value when mirrored and thus both the highest value and its mirror were
rejected. The calculation of the reference range is depicted in Figure C.11.






The number of unmeasurable results equals the measurable
Unmeasurable results reported as < 3mmol/L
[HCO−3 ]3mmol/L0mmol/L
µ = M
Figure C.11: Reference range determination – µ: mean, M : median
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The mean urine bicarbonate was 3mmol/L with a SD of 0.5mmol/L.
The reference range for urine bicarbonate was thus calculated as 2−4mmol/L.
The 90% confidence interval of the upper limit of the reference range is thus
3.8− 4.2mmol/L. A reference range for comparison could not be located.
The reference range has been calculated on a small sample with the as-
sumption of symmetry. The correct method would be to use non-parametric
analysis (requiring considerably more specimens) where results below the
LoD are assigned the value 0. One would then only need to calculate the
97.5th centile and the 90% confidence interval for that centile. A reference
range is required for validation before the urine bicarbonate test can be im-
plemented.
C.4.7 Summary of urinary bicarbonate analysis vali-
dation
The analysis of substrates indicates that, analytically, the use of NaHCO3
as a quality control (QC) material may be superior to NH4HCO3 since the
recovery and precision are greater (Table S-2 and Figures C.3 and C.4) but
the differences are negligible (Table S-2 ) when compared to the measurement
precision (Table C.1) and reference change values (Table C.3). The storage
temperature has little effect on the recovery of bicarbonate in samples stored
in microcentrifuge tubes (Figures C.5 and C.6). It is proposed that samples
should be analysed within 2h because of the improved precision compared
to samples stored for 24h (Figures C.7 and C.8).
Although a statistically significant difference exists between the analyser-
specific results of the ABG tCO2 and the DxC tCO2 (Table S-6), the effect of
the difference is insignificant (Figure C.9 and Tables S-6, C.1 and C.3). One
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can thus conclude that the results of the ABG tCO2 are comparable to the
DxC tCO2. On the DxC instrument, the functional sensitivity is 5mmol/L
and the reference range is 2− 4mmol/L.
Finally, by using the difference in recovery, rather than actual recovery,
better precision is achieved (Section C.4.5). Thus an ILC program should be
based on difference in recovery.
C.5 Proficiency testing design
Sodium bicarbonate was selected as the material for the ILC program since
it has reduced variability, lower cost, easier dissolution and is less noxious.
Furthermore, this study and a study of the effect of different sodium con-
centrations on the pKa of carbonic acid[13] indicate that the use of sodium
bicarbonate does not affect tCO2 measurement. To avoid the imprecision of
weighing small quantities of sodium bicarbonate, it is proposed that the min-
imum concentration spiked for the PT program should be 10mmol/L. An
alternative would be to use large volumes of urine such that larger masses
of sodium bicarbonate can be weighed. To avoid the increased variability
caused by the need for post-analytical dilution of high HCO−3 samples, the
maximum concentration spiked should not exceed 40mmol/L.
To negate the problem of innate urinary bicarbonate that is below the
LoD, it is proposed that the difference in recovery should be measured . The
proof that the difference in recovery is independent of initial concentration is
provided in Supplemental data S-1. In general, two measurements increase
the uncertainty of measurement[18] relative to a single measurement, but not
in this case (Section C.4.5). Lastly, since the NaHCO3 will be weighed, it
would be preferable if only one mass is weighed for all three concentrations
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and that the final concentration is obtained by varying the volume of urine
added.
The CLSI[12] provides several options for alternate assessment procedures
(AAPs) in the absence of a PT program. Eleven options (seven quantitative)
are provided that are summarised in Table C.2 by the minimum number of
laboratories for optimal implementation and the minimum number of rou-
tine patient samples required for a given time period. It is not anticipated
Many laboratories At least 1 laboratory
Average of patient results
Many tests All options Continuous re-evaluation of
reference range
Clinical correlation studies
Split sample/specimen Audit sample procedure
Few tests Manufacturer calibrant Government/university ILC
IQC data analysis
Table C.2: Comparison of alternative assessment procedures for
proficiency testing – ILC: interlaboratory comparison, IQC: internal quality
control
that many tests will be performed initially and the vast majority of patient
samples will have undetectable urine bicarbonate – below the LoD (Section
C.4.6). Thus only the AAPs that require few routine samples are potential
solutions. To avoid matrix effects, the only viable options are split sam-
ple/specimen testing and the audit sample procedure. Split sample testing
requires that a single sample should be divided into aliquots and the individ-
ual aliquots are tested by several laboratories. Audit sample testing involves
testing of stored aliquots of the same biological sample repeatedly over time
on the same assay system. Initially it is anticipated that the audit sample
procedure will have greater utility until sufficient laboratories participate to
allow split sample/specimen result interpretation. It is recognised that the
stability of bicarbonate-spiked sample, both during transport and storage,
cannot be guaranteed and that lyophilisation is not an option.
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Variants of split-specimen testing and audit-sample testing[12] are pro-
posed as potential AAPs. It is proposed that fixed quantities of sodium bicar-
bonate for spiking should be stored and transported (analogous to lyophilised
samples). The storage vessels will be 2ml (2.2ml), 1.5ml (1.65ml) and
0.5ml (0.55ml) microcentrifuge tubes. To each of the tubes add 2mg of
sodium bicarbonate (± 0.2mg). Document the amount added. When 2ml,
1.5ml and 0.5ml of urine are added to their respective microcentrifuge tubes,
the concentrations should be 11.9mmol/L, 15.87mmol/L and 47.6mmol/L
respectively. Should the amount added differ from the 2mg by δx (a small
change), the amount of urine that needs to be added is adjusted by the factor
δx/2 + 1. Although it is recognised that E(HCO−3 ) for the lower standard is
less than the functional sensitivity based on E(NH4HCO3) in Section C.4.4,
given that the recovery forNaHCO3 is greater than that forNH4HCO3 (Fig-
ure C.4), it is anticipated that the imprecision atE(NaHCO3) = 11.9mmol/L
will be less than the functional sensitivity based on E(NH4HCO3)(Equations
(C-4) and (C-6)). This is a necessary compromise to ensure that the masses
can be measured reproducibly whilst avoiding sample dilution which appears
to increase variability (Figure C.3).
Duplicate samples, each consisting of the above three specimen standards,
are sent to laboratories for testing – with the amount of urine to be added
documented. The bicarbonate analysis is conducted within 1h of adding the
urine. The purpose of two samples is to test for error in the bicarbonate
added. The laboratories can use urine from any subject and pipette the ap-
propriate amount of urine, analyse and return the results together with the
details of the instrument used. The maximum value by which corresponding
standards in each of the samples may differ (as calculated from the func-
tional sensitivity formula in Section C.4.4 and the reference change value[18]
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where the biological variation is ignored) at each of the levels is summarised
in Table C.3. It is accepted that no error in weighing the NaHCO3 has




Table C.3: Maximum allowable difference between duplicates in
proficiency testing program
occurred if the maximum allowable difference between duplicated standards
is not exceeded. Initially ILC should be conducted monthly. The monthly
ILC is defined as a QC cycle here.
For the modified split specimen procedure, the difference between the
47.6mmol/L and 11.9mmol/L specimens and the difference between the
15.87mmol/L and 11.9mmol/L specimens are plotted on a Youden[19] plot
if and only if the error in the measure of the duplicated standard results
is within the acceptable range. The requirement that the corresponding
specimen results between The Youden plots are interpreted as for any PT
program[20] with limits arbitrarily set to 2SD for all the laboratory results
or to the predicted 2SD.
For the audit sample procedure, the standard deviation index (SDI) is
plotted with respect to time and only rejected if a result falls outside of 2
SDI. The SDI is measured relative to the group SD or the predicted SD.
C.6 Prototype results
Laboratory A determined the total CO2 on a Bayer R© Rapid Lab ABG anal-
yser. Laboratory B determined the tCO2 on a Beckman-Coulter R© DxC anal-
yser. Laboratory C performed the tCO2 on both a Beckman-Coulter R© CX7
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(using the same acidification method as the DxC) and on Roche R© COBAS
B221 ABG analyser.
Samples were sent to the three laboratories, thrice during one month.
The tCO2 differences (maximum less minimum and middle less minimum)
were charted on a Youden plot (Figure C.12). Youden plots should only chart
one point per laboratory at a time. Here, the results for all three times have
been plotted. Laboratory C was unable to measure the high standard on the
third run. Due to the small sample size and the repetition of laboratories, the
Figure C.12: Total CO2 Youden plot: The solid black box represents two
standard deviations for all the samples in the plot about the median difference.
The dashed red box represents double the predicted standard deviation about the
median difference. ABG: arterial blood gas analyser
median is affected by outliers. This is most evident with the lower recovery
difference (Figure C.12). Laboratory C failed on the one occasion that tCO2
was performed on the ABG instrument. Using the more stringent criteria for
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acceptable results, by setting the limits at double the predicted SD (dashed
red box), Laboratory C failed consistently and Laboratory A failed once.
Laboratories A and B have proportional error, while laboratory C’s error is
not proportional.
The EQA was also evaluated using the SDI for the three laboratories.
The y-axis represents the SDI for the upper difference and is relative to the
sample’s upper difference SD at that sample number (C.13). The dashed red
lines represent SDI two units where the SD is the predicted SD.
Figure C.13: Total CO2 upper difference SDI plot: The dashed red
lines represent two standard deviation index units (based on predicted standard
deviation). ABG: arterial blood gas analyser
The SDIs for the lower differences were acceptable for all the laboratories
(Figure C.14). The dashed red lines represent two SDI units when normalised
to the predicted SD for the lower recovery difference.
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Figure C.14: Total CO2 lower difference SDI plot: The dashed red
lines represent two standard deviation index units (based on predicted standard
deviation). ABG: arterial blood gas analyser
The recovery of the upper difference was acceptable for all but one labo-
ratory (Figure C.15). The dashed red lines represent the acceptable recovery
range based on Section C.4.5. Laboratory C under-recovered significantly.
Similarly, in the lower difference recovery (Figure C.16), the dashed red lines
represent the predicted acceptable range of recovery. Again, the wide range
is indicative of the imprecision at these analyte levels.
C.7 Discussion of pilot study of the ILC pro-
gram
This pilot study of the ILC program has highlighted a need for a proficiency
testing program for urine bicarbonate because it is evident that laboratory
C is performing suboptimally.
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Figure C.15: Total CO2 upper difference recovery: The dashed red
lines represent the predicted range of recovery results. ABG: arterial blood gas
analyser
Figure C.16: Total CO2 lower difference recovery: The dashed red
lines represent the predicted range of recovery results. ABG: arterial blood gas
analyser
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Despite the limited number of samples and the pooling of all the labo-
ratory results, the Youden plot (Figure C.12) detected flaws in laboratory
C’s ABG analyser measurements and in its Beckman-Coulter tCO2 at the
more stringent criteria of predicted SD. Laboratory A appears flawed for one
run, but this is a consequence of the median being distorted by the results of
laboratory C. The distortion of the median is due to the low specimen num-
ber and using multiple results from the same laboratories. Laboratory A is
performing within limits, as evidenced by the recovery experiments (Figure
C.15).
The flaw in laboratory C’s results is highlighted by the upper difference
SDI plot (Figure C.13). Importantly, the SDI plots (Figures C.13 and C.14)
do not suggest a flaw in laboratory C’s PT results – evident in the Youden
plot (Figure C.12). Thus, the SDI plots and the Youden plot are comple-
mentary.
The inherent flaw in both the SDI and Youden plots is that the sample
median does not necessarily reflect the true value. The recovery experiments
are complementary to the SDI and Youden plots by being relative to a higher
(here gravimetric) standard. Thus, the upper difference recovery plot (Figure
C.15) provides information on the quality of the recovery.
The wide acceptable limits for the lower recovery difference (Figures C.14
and C.16) diminishes the ability of this metric to detect a flaw. The origin
of the wide limits is the reduced precision at the lower recoveries used to
determine the recovery difference. The effect of the variability on the CV of
the lower recovery difference is compounded by the small difference between
the 11.9mmol/L and 15.9mmol/L standards.
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A marginal cost analysis was performed in order to ensure that the ILC
program is cost effective (Supplemental S-2).
C.8 Conclusion
An interlaboratory comparison program has been designed for an unstable
analyte (HCO−3 ) that is only infrequently measured in a few laboratories.
The program relies on the measurement of the difference in recovery of total
CO2 in urine samples spiked with NaHCO3. Matrix effects and instability
associated with transport and refrigeration are minimised by adding fresh
human urine to the dry reagent within 1h of analysis.
The procedure can be generalised to certain classes of unstable analytes
that are only infrequently measured at a few laboratories (eg. acetoacetate
and pyruvate).
The design of the program was based on a series of experiments comparing
ammonium bicarbonate to sodium bicarbonate (in urine) on two analysers.
Sodium bicarbonate was a superior analyte in terms of analytical perfor-
mance and cost. A reference range was established based on 23 specimens
and although the sample size may be sub-optimal, the utility of more de-
tailed reference range analysis is debatable, given that the range is less than
the functional sensitivity. The functional sensitivity proved to be more use-
ful than the limit of detection in assessing the analytical performance of the
assay. The limit of detection and the limit of blank could not be determined
because the analyser could not be set to read to this level. Values less than
5mmol/L are reported as < 5mmol/L. The analyser can be adjusted to
read to ≥ 3mmol/L.
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The initial implementation of the AAP has proven to be successful and
should continue to be implemented in the Western Cape. The ABG instru-
ment performed better than the DxC analyser, in terms of both recovery and
variability, even though tCO2 is measured indirectly by the ABG analyser
and directly by the DxC. This is likely to be due to the reduced delay in pro-
cessing on the ABG, such that the specimen is exposed to air for a shorter
period.
The cost of running the ILC (Supplemental S-2) is R4, 64 per QC cycle
per laboratory where a QC cycle comprises 6 recovery of bicarbonate tests.
It is proposed that one QC cycle should occur each month. The marginal
cost[21] of performing the ILC on the Beckman-Coulter DxC R© is R17, 64
(ILC plus reagent costs). The marginal cost of performing the ILC on an
arterial blood gas analyser is only the cost of the ILC program (R4, 64) be-
cause of the nature of the lease agreement.
It is proposed that both the urine bicarbonate samples and QC samples
be analysed on the arterial blood gas analyser, since it is more cost effective
and the urine is exposed to the atmosphere for a shorter period of time.
The value of the lower recovery difference may be improved by increasing
the concentration of the middle recovery level (15.9mmol/L). Increasing the
middle recovery level to 23.9mmol/L by reducing the volume of urine added
to the 1.5ml microcentrifuge tube to 1.0ml, should reduce the acceptable
limits of the lower recovery difference (Figures C.14 and C.16).
Clinically, the design and implementation of the EQA program will fa-
cilitate multicenter trials, allow comparison of laboratory results and allow
epidemiological studies on the prevalence of RTA in various groups.
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This dissertation constructed a PT program and evaluated tCO2 deter-
mined by acidification of all bicarbonate species to CO2 and then measuring
with a CO2 electrode on an automated analyser. A second method deter-
mined pH and pCO2 using H+ and CO2 electrodes respectively, and then
calculating tCO2 on an ABG analyser. The latter appears to be more precise.
It is believed that the improved precision of the ABG analyser is because the
sample is exposed to air for a shorter period of time – HCO−3 is volatile.






where PEP is phosphoenolpyruvate and the resultant oxaloacetate is mea-






However, based on the improved precision of the ABG (presumed due to less
air exposure), this dissertation predicts that the precision of the enzymatic
method, on an automated analyser, will be compromised by the delay in
processing during which the specimen will be exposed to air.
79
C.9 Acknowledgments
We should like to thank the National Health Laboratory Service K-fund for
the resources required to perform this study.
The enthusiastic support of the National Health Laboratory Service chem-




1. Unwin R, Capasso G (2001) The renal tubular acidoses. J R Soc Med 94:221–
225
2. Halperin ML, Goldstein MB, Haig A, Johnson MD, Stinebaugh BJ (1974)
Studies on the pathogenesis of type I (distal) renal tubular acidosis as revealed
by the urinary pCO2 tensions. J Clin Inv 53:669–677
3. Bagga A, Bajpai A, Menon S (2005) Approach to renal tubular disorders.
Indian J Pediatr 72(9):771–776
4. Li H, Adeli K (2009) Laboratory quality regulations and accreditation stan-
dards in canada. Clin Biochem 42:249–255
5. Guzel O, Guner EI (2009) ISO 15189 accreditation: Requirements for quality
and competence of medical laboratories, experience of a laboratory I. Clin
Biochem 42:274–278
6. Dhatt GS, Peters S (2002) Accreditation of medical laboratories in South
Africa. Accred Qual Assur 7:290–292
7. Uras F (2009) Quality regulations and accreditation standards for clinical
chemistry in Turkey. Clin Biochem 42:263–265
8. Davies KW (1999) Quality assurance in clinical chemistry laboratories in the
UK. Accred Qual Assur 4:18–26
9. Andersen V, Bednarova M (2010) EU regulation for accreditation. Accred Qual
Assur doi:10.1007/s00769-010-0688-3
10. Rabinovitch A (2002) The College of American Pathologists laboratory ac-
creditation program. Accred Qual Assur 7:473–476
11. South African National Accreditation System (2010), Search for ac-
credited bodies and laboratories in the SANAS directory. URL
http://www.sanas.co.za/directory/med_default.php
81
12. CLSI (2008) Assessment of laboratory tests when proficiency testing is not
available; approved guideline – second edition. Tech. rep., Clinical and Labo-
ratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Penn-
sylvania 19087-1898 USA
13. Gonzalez SB, Voyer LE, Corti S, Quadri BE, Gogorza C, Bortolazzo C, Al-
varado C (2004) Determination of urinary bicarbonate with the Henderson-
Hasselbalch equation comparison using two different methods. Pediatr Nephrol
19:1371–1374
14. Kurtz I, Kraut J, Ornekian V, Nguyen MK (2008) Acid-base analysis: a
critique of the stewart and bicarbonate-centered approaches. Am J Phys-
iol Renal Physiol 294(5):F1009–F1031, doi:10.1152/ajprenal.00475.2007, URL
http://dx.doi.org/10.1152/ajprenal.00475.2007
15. Beckman-Coulter. Inc, 4300 N. Harbor Blvd Fullerton, CA 92835 (2008)
Chemistry Information Manual Synchron R© Clinical Systems
16. Bayer HealthCare LLC, East Walpole, MA 02032 (1996) Rapidlab 348
pH/Blood Gas Analyzer [Package Insert]
17. Gamble J (1922) Carbonic acid and bicarbonate in urine. J Biol Chem 51:295–
310
18. White G, Farrance I (2004) Uncertainty of measurement in quantitative med-
ical testing - a laboratory implementation guide. Clin Biochem Rev 25(Suppl
II):S1–S24
19. Westgard JO, Klee GG (2006) Tietz textbook of clinical chemistry and molec-
ular diagnostics, chap. 19. 4th edn., Elsevier-Saunders, 515–516
20. Boley NP, Bièvre PD, Taylor PD, Uldall A (2001) Requirements vs accept-
ability in proficiency testing schemes and other interlaboratory comparisons.
Accred Qual Assur 6:244–251
82
21. Travers E (1997) Clinical laboratory management, chap. 28. 1st edn., Williams
& Wilkins, Baltimore, 528–549
22. Forrester RL, Wataji LJ, Silverman DA, Pierre KJ (1976) Enzymatic method
for determination of co2 in serum. Clin Chem 22(2):243–245
Supplementary data
S-1 Recovery difference: proof of concept
Let the initial (before spiking) HCO−3 concentration of a random urine (Ux)
be c. Let two containers have volumes V1 and V2, respectively. If, to each
container, a volume of urine (Ux) is added, the amount of bicarbonate added
to each container is
n1 = c× V1 (S-1)
n2 = c× V2 (S-2)
Let the amount spiked into each container be N1 and N2, respectively. Thus
the amount of HCO−3 in each container is n1 +N1 and n2 +N2, respectively.
















Thus the difference in the measured concentrations, (S-3) - (S-4), is












which is independent of the original urine concentration c. For this disser-
tation, the difference in recovery is defined by the left-hand-side of (S-5) or
c1 − c2.
S-2 Proficiency testing costing
Initially this ILC program is intended to be implemented at the tertiary aca-
demic hospitals of the Western Cape – three NHLS laboratories.
Given the low test volume, the ILC program will be implemented from
one of the above laboratories – whichever has the most spare capacity. The
indirect costs will therefore be borne by the routine diagnostic laboratory. No
capital expenditure is required. Several of the direct costs are also negated
by existing infrastructure. In particular, a transport system exists between
these laboratories, (given that the program will be assigned to the labora-
tory with excess capacity) no additional labour costs are incurred (25 minutes
per laboratory are required to prepare the QC samples), there are no special
storage or transport requirements for sodium bicarbonate and results will be
transmitted electronically.
Thus the only direct costs to be considered are direct materials (sodium
bicarbonate and microcentrifuge tubes) and consumables – paper. All costs
are calculated per institution per QC cycle (once a month) with a 10% margin
of error included. Each institution uses 2mg of sodium bicarbonate per test
and there are six tests in a QC cycle. Thus, per institution, up to 13.2mg of
sodium bicarbonate is used costing R2, 11. The two 0.6ml microcentrifuge
tubes used by each institution cost R0.67, the two 1.5ml microcentrifuge
tubes collectively cost R0, 68 and the two 2.0ml microcentrifuge tubes cost
R0, 86. Thus the direct materials per institution per QC cycle is R4, 32. The
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two pages (to be used as hardcopy) cost R0, 32. Thus the total cost is R4, 64.
Note that the cost of performing the test is not included – this cost is
not included when paying for an EQA program. The cost of performing a
test is R35, 39 (the price that the NHLS would charge a client). Six tests are
performed per institution per QC cycle thus totaling R212, 34 per institution
per QC cycle. Each set of three tests results in two recovery difference levels.
The cost (to the institution) of printing the results for its own record keeping
is R0, 32.
Thus the cost to subscribe to the ILC (including samples and reports) is
R4, 64 per cycle per institution. The charge to perform the test is R212, 66.
Thus the total cost to the laboratory is R217, 30 per QC cycle.
It should be noted that cost of performing the test includes both direct
and indirect costs that should be negated as they are borne by the routine
diagnostic tests. Negating the direct and indirect costs that are borne by
the routine diagnostic tests, the marginal cost[1] of performing the ILC on
a Beckman-Coulter DxC R© (ILC cost plus reagents for tCO2) is R17, 64 per
QC cycle where the reagents are buffer (R8, 00 for 6 tests), reference material
(R2, 10 for 6 tests), acid reagent (R1, 33 for 6 tests), pipette tips (R0, 11 for
1), transfer pipette (R0, 63 for 6) and cups (R0, 81 for 6).
The lease agreements for the ABG analysers include a fixed number of
tests per month that is in excess of utilisation. Thus the marginal cost of
performing the ILC on these analysers is R0, 00. Consequently (for a labo-
ratory using an ABG analyser) the marginal cost of the ILC per laboratory
per QC cycle is only the cost of participating in the ILC program which is
R4, 64 per laboratory per QC cycle.
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Thus for 12 QC cycles per year, the marginal cost of urine bicarbonate
QC on the DxC is R211, 68 per year and for an ABG the marginal cost is
R55, 68 per annum.
S-3 Tabular summaries of raw data
The description of the ammonium bicarbonate and sodium bicarbonate mea-
surements at the three HCO−3 decision levels (13.5, 27 and 54mmol/L) indi-
cates that the measurements on the 2 anlaysers are comparable (Table S-1).
The table shows the count, mean, median, 5th and 95th percentiles of the bi-
carbonate concentration for the two compounds (NaHCO3 and NH4HCO3).
The p value for the Shapiro-Wilk test of normality indicates that normality
cannot be excluded (Table S-1).
Decision level Substrate n mean median 5th 95th p
13.5mmol/L NaHCO3 20 11.3 10.8 8.3 13.5 0.22
NH4CO3 20 10.2 10 7.7 13.1 0.37
27mmol/L NaHCO3 20 23.1 23 17.8 30.5 0.48
NH4CO3 20 19.5 19.0 15.8 24.0 0.08
54mmol/L NaHCO3 20 43.0 41.3 35.4 54.3 0.09
NH4CO3 20 42.1 41.6 37.0 47.6 0.43
Table S-1: Description of NH4CO3 vs NaHCO3 HCO3 concentra-
tion comparison data – p: p-value of the Shapiro-Wilk test for absence of
normality (p ≤ 0.05 is significant), n: count
The inferential statistics comparing theHCO−3 concentration ofNaHCO3
and NH4CO3 (using the paired student t-test) indicates that statistically sig-
inificant differences exist (Table S-2). The p value in Table S-2 indicates the
statistical significance of the t-test comparing the NaHCO3 and NH4CO3
HCO−3 concentration by decision level. The difference column refers to the
mean of difference – an indication of the effect (or contribution) of the differ-
ence between the measured values for HCO−3 when using NaHCO3 versus
S-5
NH4HCO3.
Decision level n p difference 95% CI
13.5mmol/L 20 0.02 −1.1mmol/L [−1.95,−0.22]
27mmol/L 20 3× 10−4 −3.62mmol/L [−5.35,−1.89]
54mmol/L 20 0.43 −0.93mmol/L [−3.33, 1.47]
Table S-2: Summary of paired student t-test comparison between
NH4CO3 and NaHCO3 bicarbonate concentrations by decision
level – p: p-value of the paired student t-test (p ≤ 0.05 is significant), n: count,
difference is the mean of the differences between the NH4HCO3 and NaHCO3
results and the 95%CI is the 95% confidence interval for the mean of the differences
The raw data were used to construct Figure C.3 in Section C.4.1. Of note,
although a statistically significant difference exists between the HCO−3 con-
centrations determined usingNaHCO3 versusNH4CO3 as substrate for each
of the decision levels (Table S-2), the contribution of the difference is negligi-
ble when compared to the imprecision of the measurement and the reference
change values (Tables C.1 and C.3, respectively).
The descriptive and inferential data for the effect of temperature on the
specimens stored for 2h and 24h indicate that statistically significant dif-
ferences due to storage temperature do not exist (Table S-3). Increasing
sample size may show statistically significant differences but should such an
effect exist, it would be negligible compared to instrument imprecision and
the reference change values (Tables C.1 and C.3, respectively). In Table S-3
the results are stratified by decision level. The p value is the result of the
one-way analysis of variance (ANOVA). ANOVA was performed because nor-
mality could not be excluded on the Shapiro-Wilk test.
Similarly, storage time did not have a statistically significant effect on
HCO−3 recovery (Table S-4). When the differences in recovery due to stor-
age time are compared to measurement uncertainty and reference change
values (Tables C.1 and C.3), there appears to be no value to increasing sam-
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Bicarbonate concentration (mmol/L)
Time Temp 13.5 95%CI 27 95%CI 54 95%CI
2h
Initial 10.2 [9.4, 11.0] 20.0 [18.7, 21.4] 42.1 [40.3, 43.9]
RT 9.5 [8.6, 10.4] 19.4 [17.7, 21.1] 40.8 [38.5, 43.1]
4◦C 9.7 [8.8, 10.6] 19.4 [17.7, 21.1] 41.1 [39.0, 43.1]
p 0.50 0.65
24h
Initial 10.2 [9.4, 11.0] 20.0 [18.7, 21.4] 42.1 [40.3, 43.9]
RT 9.4 [8.4, 10.5] 18.0 [15.8, 20.1] 39.8 [37.2, 42.4]
4◦C 10.1 [8.8, 11.4] 19.0 [17.0, 21.0] 40.3 [37.8, 42.7]
p 0.56 0.36
Table S-3: Descriptive and inferential data for the effect of
storage temperature on bicarbonate recovery stratified by de-
cision limit – concentrations are in mmol/L, p: p-value of one-way ANOVA
(p ≤ 0.05 is significant), RT: room temperature, Temp: temperature
ple size to show a statistically significant difference.
Bicarbonate concentration (mmol/L)
Temp Time 13.5 95%CI 27 95%CI 54 95%CI
RT
Initial 10.2 [9.4, 11.0] 20.0 [18.7, 21.4] 42.1 [40.3, 43.9]
2h 9.5 [8.6, 10.4] 19.4 [17.7, 21.1] 40.8 [38.5, 43.1]
24h 9.4 [8.4, 10.5] 18.0 [15.8, 20.1] 39.8 [37.2, 42.4]
p 0.44 0.26 0.38
4◦C
Initial 10.2 [9.4, 11.0] 20.0 [18.7, 21.4] 42.1 [40.3, 43.9]
2h 9.7 [8.8, 10.6] 19.4 [17.7, 21.1] 41.1 [39.0, 43.0]
24h 10.1 [8.8, 11.4] 19.0 [17.0, 21.0] 40.3 [37.8, 42.7]
p 0.78 0.69 0.50
Table S-4: Descriptive and inferential data for the effect of
storage time on bicarbonate recovery stratified by decision
limit – concentrations are in mmol/L, p: p-value of one-way ANOVA (p ≤ 0.05
is significant), RT: room temperature
The descriptive data for TCO2 as determined on the RapidLab R© 348
blood gas analyser and the Beckman-Coulter DxC R© analyser excludes nor-
mality using the Shapiro-Wilk test (Table S-5).
Given the absence of normality (Table S-5), the Wilcoxon test was used
to test for significant differences between the ABG and DxC samples (Table
S-6). The inferential data (Table S-6) shows statistically significant differ-
S-7
Decision Analyser n mean median 5th 95th p
level
13.5mmol/L DxC 47 9.9 9.3 6.5 16.3 0.01ABG 47 8.2 7.4 4 14.2 0.02
27mmol/L DxC 48 19.7 17.6 10.1 37.1 3.3× 10
−9
ABG 48 18.9 16.6 7.5 46 6.9× 10−7
54mmol/L DxC 48 41.1 39.3 30.3 50.9 2.9× 10
−6
ABG 48 39.0 37.1 24.8 53.7 2× 10−3
Table S-5: Description of ABG and DxC TCO2 concentration
comparison data – p: p-value of the Shapiro-Wilk test for absence of normal-
ity (p ≤ 0.05 is significant), n: count, ABG: RapidLab R© 348 blood gas analyser,
DxC: Beckman-Coulter DxC R© analyser
ences between the ABG and DxC results.
Decision level n p difference 95% CI
13.5mmol/L 47 2.2× 10−7 1.8mmol/L [1.3, 2.3]
27mmol/L 48 6× 10−3 1.4mmol/L [0.45, 2.25]
54mmol/L 48 5.8× 10−5 2.2mmol/L [1.28, 3.15]
Table S-6: Summary of Wilcoxon-test comparison between ABG
and DxC bicarbonate concentrations by decision level p: – p-
value of the Wilcoxon-test (p ≤ 0.05 is significant), n: count, difference is the
median differences between the ABG and DxC results and the 95%CI is the 95%
confidence interval for the median of the differences
Although statistically significant differences have been detected between
the ABG and DxC analysers, the contributions of these differences (S-6) are
not significant when compared to either the imprecision of the measurement
or the reference change values (Table C.1 and Table C.3 respectively).
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D-1
D1: An introduction to clinical
acid-base theory
Of the original 5 properties of acids defined by Boyle[1], only 2 remain valid
and are:
• change blue plant dyes to red and
• lose the above property on contact with bases.
Thus acids are recognised by these properties.
In clinical chemistry, traditional Henderson-Hasselbalch based theories[2]
and a recent physicochemical theory[3] exist to explain acid-base disturbance.
The evaluation of these theories requires that two basic science questions
should be answered[4]. The first, a physical chemistry question, is upon which
acid-base model is the theory based and the second, a physiology question, is
does the theory explain an underlying mechanism/physiology/pathophysiology
(ie the regulatory factors)? The final question is an applied science question
(a clinical question): does one theory provide different/more management
information than the other? To critique these theories one has to recognise
that there are two realms in which the discourse occurs. The first realm or
space is descriptive and is described in the language of mathematics, and the
second space is explanatory and is in the language of physiology. The sep-
aration of these spaces (descriptive and explanatory) will be achieved with
D1-2
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the introduction of a distinct vocabulary for each.
D1.1 Nomenclature
The convention here is that the term ‘variable’ refers to unknowns in a
mathematical equation and that variables can either be independent (deter-
mined experimentally) or dependent (calculated from independent variables)
– terms that will also be reserved for mathematical descriptions. With regard
to regulatable outcomes (like pH), the term ‘factor’ will refer to underlying
pathophysiological mechanisms and can either be regulated (physiological
processes actively manipulated to achieve a desired outcome) or unregulated
(inevitable consequence of regulated factors to maintain physical laws) –
where regulated and unregulated are reserved for the underlying pathophys-
iology. Factors can either be associated (a change in one factor cannot be
achieved without changing the other) or unassociated (one factor can be
changed arbitrarily without changing the the other). Similar terms in the
various spaces are summarised in Table D1-1 where ‘variable’ and ‘factor’ are








Table D1-1: Similar terms in the descriptive and explanatory
spaces
and unregulated factors can be either associated or unassociated and that
there is no equivalent in the mathematical description of this dissertation.
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D1.2 History of acid-base theory
Lavoisier proposed an oxygen-centric acid-base theory in 1776[1, 5]. This
was followed by the hydrogen(proton)-centric[5] models of Arrhenius(1884)
and then Brønstead-Lowry(1923). Since then, more comprehensive, electron-
centric theories have been constructed by Lewis(1923 and restated in 1939)[1,
6], Usonovich(1939)[1, 5] and Pearson(1963)[7, 8] which explain the known
acidic properties of non-hydrogen containing molecules and ions. In particu-
lar, Lewis acids are molecules, radicals or ions that can accept a non-bonding
electron pair, in order to complete its valence shell, from another atom[1, 6, 9].
A brief introduction to Lewis-Acid base theory is provided in Appendix D3.
D1.3 Traditional acid-base theory in clinical
chemistry
Bicarbonate (HCO−3 ), a base in the proton-centric theories[9], is considered
fundamental to clinical acid-base regulation because, in vivo, it does not
reach equilibrium as carbonic acid can dissociate into H2O and CO2[2, 10]
and the latter can be eliminated by the lungs. This dissociation is described
by Reaction <D1-1>.
HCO−3 +H+ EGGGGGCH2CO3 EGGGGGCCA
CO2 +H2O <D1-1>
The dissociation of H2CO3 is catalysed by carbonic anhydrase(CA). In 1909
(six years after Arrhenius was awarded the Nobel prize in chemistry) the Hen-
derson Equation (D1-1), a statement of the law of mass action for Reaction
<D1-1>, was constructed:








where CO2 is the dissolved carbon dioxide and HCO−3 is the dissolved bicar-
bonate. Applying Sørenson’s convention of expressing the H+ concentration
in pH units[11], such that
pH := − log[H+], (D1-2)
to Equation (D1-1); the Henderson-Hasselbalch formula is derived:
pH = pK1 + log
[HCO−3 ]
[H2CO3]




where sCO2 is the solubility of CO2 and PCO2 is the partial pressure of
CO2. The right-hand-side of (D1-3) is the Henderson-Hasselbalch equation.
It should be noted that (D1-1) was published before the Brønstead-Lowry
acid-base theory and that the left-hand-side of (D1-1) is an Arrhenius acid.
The latter statement is obvious when considering Reaction <D1-2>.
H2CO3 +NaOH 
 NaHCO3 +H2O <D1-2>
Nevertheless, when considering Reaction <D1-1>, HCO−3 can also be con-
sidered a Brønstead-Lowry base (a superset for Arrhenius bases). Further-
more, the derivation is for an equilibrium state and is a one compartment
model that only applies to the extra-cellular fluid. Finally, Henderson was
aware of the buffering capacity of non-carbonate species[12, 13] but only con-
sidered them significant once the bicarbonate reserve had been significantly
depleted[13] and would not have considered the effect of Lewis acids (serum
cations likeNa+ and Ca2+ as discussed in Appendices D3.1 and D3.3). Given
that this is a proton-centric model of acid-base disturbance, it cannot pre-
dict the effect of electrolytes on pH. Only PCO2 and pH are measured
directly[14]. There are a maximum of nine possible states (combinations of
the independent variables)[15] and observation correlated these states with
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combinations of altered respiration and altered net acid secretion (NAE) – a
function of H+ and HCO−3 [15].
One should therefore deduce that, although the right-hand-side of Reac-
tion <D1-1> forms a Brønstead-Lowry acid-base conjugate pair, the Henderson-
Hasselbalch equation was based on an Arrhenius acid-base model[12, 13].
Equation (D1-3) only applies to the extra-cellular space at equilibrium when
all the non-carbonate buffers and the electrolytes do not deviate substantially
from normal[16] – the effect of Lewis acids is constant. In Equation (D1-3),
PCO2 and pH are independent variables and HCO−3 is dependent but exper-
imental data suggest that PCO2, pH and HCO−3 are regulated factors. Thus
dependent variables do not imply unregulated factors – proof provided in Ap-
pendix D2.1. The proof of the converse is provided in Appendix D2.2. Note
that only Na+, Mg2+, Fe3+ and Al3+ and NH3 should in principle have the
potential to modify acidity[8, 17]. Thus the Henderson-Hasselbalch equation
deviates quantitatively when electrolytes are different from normal but may
not deviate qualitatively. Finally it should be recognised that initially the
Henderson-Hasselbalch equation was a description (not an explanation) and
that only subsequent observation[15] and experiment could attach physiolog-
ical explanation.
With the introduction of the van Slyke equation and base excess (BE)
[14, 15, 18], effectively a two compartment model (incorporating intracel-
lular haemoglobin) was applied to the principles underlying the original
Henderson-Hasselbalch equation. Equation (D1-4) is a version of the van
Slyke equation[19]
BE = [HCO−3 ]− 24.4 + (2.33[Hb] + 7.7)× (pH − 7.4)× (1− 0.23[Hb])
(D1-4)
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where pH and HCO−3 are calculated from (D1-3)[4, 18, 19].
Apart from the theoretical limitations above, practical limitations exist.
PCO2 and pH are independent variables in (D1-3) and are measured as
such. However these factors are associated – at least one argument in the
great trans-Atlantic debate[9, 20]. The Copenhagen group in the great debate
circumvented the problem by calculating BE (the concentration of titratable
H+ required to return the pH of in vitro whole blood to 7.4 at 37◦C, with
PCO2 held at 40mmHg[19]) from (D1-4) and introducing standard base
excess (SBE) [21] – which standardises BE to a haemoglobin concentration
of 5 g/dL[22]. However, this solution has also been criticised because the in
vitro results do not not reflect the in vivo situation[10, 19, 21].
D1.4 Evaluating Stewart’s contribution
At least two components exist to Stewart’s contribution to acid-base phys-
iology. The first is descriptive and the second is explanatory. With regard
to description, given the discrepancy between in vivo and in vitro measure-
ments, the option exists to circumvent the above problems associated with
the direct measurement of H+ by indirect measurement. The above action is
only justified if no discrepancy exists between in vivo and in vitro measure-
ment of the indirect factors. Stewart applied electroneutrality to determine
[H+]. Thus the difference between all the anions and cations should be a
function of [H+][3, 23]. Two differences should be recognised between Stew-
art’s approach and an earlier attempt (buffer base) in 1948[23]. The latter
also considered the effect of non-carbonate buffers (grouping them into buffer
base or SID) but did not isolate the non-carbonate buffers[23] for interpre-
tation (the equivalent of [AT OT ]) and a flawed interpretation of acids and
bases was used[24, 25].
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D1.4.1 Acid-base model type
It is thus evident that Stewart’s contribution is a proton-centric model and
can therefore not explain the contribution of non-protonated ions to acidity.
The proof that Stewart’s theory is not compatible with more comprehensive
theories in physical chemistry is provided in Appendix D2.3. Stewart’s use of
the water dissociation constant to determine the relationship between [H+]
and [OH−] is consistent with an Arrhenius model of acid-base[3].
Thus, in theory, the model should provide no information beyond the
constraints of an Arrhenius model. It has already been shown that the
Henderson-Hasselbalch equation is also an Arrhenius theory for determin-
ing [H+]. Thus, equating Stewart’s formula[3] for [H+] to (D1-1),
[H+]3 = KAK ′w + (K ′w +KA ([AT OT ]− [SID])) [H+]







where either SIDapp or SIDeff (which should be equal) can be substituted





































= [Alb]× (0.123× pH − 0.631) (D1-8)[
Pi−
]





+ 0.28 [Alb] (g/L) + 1.8 [Pi] (mmol/L) (D1-9)
AT OT = 0.344 [Total protein] = 0.572 [Alb] . (D1-10)
The Stewart theory adherents follow Equation (D1-5) and the traditional-
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ists follow (D1-6). It has been shown explicitly that the one compartment
descriptions are identical[16, 24, 28] such that (D1-3) can be restated as
pH = pK1 + log
SID − [AT OT ]
sCO2 × PCO2
. (D1-11)
It is counter-intuitive that a reduction in [AT OT ], a buffer in the traditional
approach, should produce alkalosis. However, in the Stewart approach, al-
bumin is viewed as weak acid (potential proton-donor) thus a reduction in
weak acid induces an alkalosis[26].
A two compartment model has been constructed by Wooten[29]. Fig-
ure D1-1 compares the two theories with regard to the available acid-base









Figure D1-1: Venn diagram comparing the number of compart-
ments described by various models
an Arrhenius acid and is a one-compartment model that only applies in the
extracellular space at equilibrium when the buffers and electrolytes do not
deviate substantially from normal. The last statement is not obvious. The
origin is that there are implicit assumptions about the dissociation of water in
the presence of ions. In particular, the theory treats all ions as equal (which
the Lewis acid-base theory refutes as demonstrated in Appendix D2.3). It
is apparent that the original Stewart theory suffers from the same flaws as
the Henderson-Hasselbalch theory and should also be inaccurate when elec-
trolytes or proteins deviate substantially from normal[4]. The relationship
between the clinical chemistry acid-base models and the physical chemistry
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Figure D1-2: Venn diagram comparing the clinical chemistry mod-
els to the physical chemistry acid-base theories
At a practical level, in (D1-6), [H+] and PCO2 are independent vari-
ables and [HCO−3 ] is dependent whereas, in (D1-5), AT OT and [SID] are
independent variables and [H+] is dependent. Although the difficulties as-
sociated with the measurement of in vivo factors in vitro are avoided using
(D1-5) (because the results of the measurements are the same in vitro and
in vivo), the uncertainty of measurement increases[30]. One has the option
of using (D1-5) to calculate [H+] in (D1-6), measuring tCO2 to calculate
CO2 + HCO−3 and then solving the simultaneous equations – which should
provide compatible in vitro and in vivo results. In summary Stewart’s theory
is an alternate means of determining H+.
D1.4.2 Stewart theory physiology
The second component of Stewart’s theory is the explanation of the physi-
ology – the ion equilibrium model of acid-base demonstrates that this com-
ponent is superfluous[10]. Similarly, it is unfortunate that the Henderson-
Hasselbalch description is not separated from the physiological explanation[15].
Stewart deduces that independent variables imply and are implied by regu-
lated factors and conversely that dependent variables imply and are implied
by unregulated factors[3]. Intuitively one cannot deduce the underlying phys-
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iology from the mathematical description[4] and the proof is provided in Ap-
pendices D2.1 and D2.2.
Although Stewart’s deduction is flawed, the results may not be. The avail-
able evidence indicates that urine acidification is a combination of HCO−3
reabsorption and H+ secretion. The former is explained (using Stewart’s ap-
proach) byHCO−3 reabsorption, on the basolateral membrane of the proximal
tubular cell (Figure B.2), being mediated by the kidney sodium bicarbonate
co-transporter (kNBC)[31] – Na+ increases SID[32] in Equation (D1-11).
Similarly the secretion of H+, by the α-intercalcated cells of the distal con-
voluted tubule requires the kidney anion exchanger (kAE)[31], on the ba-
solateral membrane, to reabsorb HCO−3 in exchange for serum Cl− (Figure
B.3) – increasing SID[32] in (D1-11).
Until the mechanism by which a putative H+ or HCO−3 sensor regulates
kNBC and kAE directly or a putative SID or AT OT sensor directly regulates
kNBC and kAE is elucidated, it cannot be determined whether Henderson-
Hasselbalch or Stewart respectively, explain which factors are regulated[4].
Note that H+ is the strongest Lewis acid and if acidosis is regulated, it
is appropriate that H+ should be regulated directly. The alternative is to
accept that acid-base disturbance is the penalty for electrolyte disturbance.
Finally both descriptions accept the respiratory regulation of CO2 which is
directly related to H2CO3 and H+ by (D1-3).
D1.4.3 Application of Stewart theory
Regarding diagnosis, in (D1-3) there are two independent and one depen-
dent variable. Consequently there are nine possible states[15] of which seven
(including normal) are recognised clinically[33]. Equation (D1-11) has three
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independent variables and one dependent variable and consequently twenty-
seven potential states exist. The number of potential states can, however,
be increased arbitrarily (Appendix D2.4). Thus the number of potential
states described is not a criterion by which to assess the clinical utility of
each approach. Nevertheless, it is evident that Stewart’s theory can iden-
tify more categories of acid-base disturbance – twelve categories (including
normal) are recognised and summarised in Table D1-2[26]. Stewart’s the-
Acidosis Alkalosis
Respiratory ↑ CO2 ↓ CO2
Non-respiratory(metabolic)
(a) Abnormal SID
(i) Water excess/deficit ↓ SID, ↓ [Na+] ↑ SID, ↑ [Na+]
(ii) Imbalance of strong anions
(α) Chloride excess/deficit ↓ SID, ↑ [Cl−] ↑ SID, ↓ [Cl−]
(β) Unidentified anion excess ↓ SID, ↑ [XA−]
(b) Non-volatile weak acids (AT OT )
(i) Serum albumin ↑ [Alb] ↓ [Alb]
(ii) Inorganic phosphate ↑ [Pi] ↓ [Pi]
Table D1-2: Classification of primary acid-base disturbances by
Stewart’s approach[26]
ory is able to distinguish low SID acidosis being masked by compensating
hypoalbuminaemia[33, 34]. Furthermore the acid-base disturbances listed in
Table D1-2 may not traditionally be recognised as such but would be inter-
preted as hypo/hypernatraemia, hypoalbuminaemia or hypophosphataemia[24].
Usually the two approaches describe the same acid-base disturbance but the
aetiology is interpreted differently[26, 33]. However, traditionally, for a find-
ing of hypoalbuminaemia with metabolic acidosis, the hypoalbuminaemia
would not be considered causal[24, 26].
Effectively, Stewart’s approach (using SID) corrects HCO−3 for partially
dissociated ions (‘weak acids’/non-carbonate buffers). The utility of cor-
recting the [HCO−3 ] for the contribution of albumin and phosphate has,
traditionally, been considered insignificant[12, 13] and later not considered
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because of its insignificance[23]. However, by 1928, there was evidence of
significant albumin cation binding capacity[35, 36] – relevant when calcu-
lating the anion gap. In vitro, albumin buffering is significant[37–39] and
plasma protein buffering capacity may be double that of bicarbonate[40]. In
vitro, haemoglobin is responsible for 79% of the buffering and plasma (bi-
carbonate, protein and inorganic phosphate) is responsible for the remaining
21%[40]. In vivo, a rat model which determines whole blood buffering ca-
pacity in the presence of acute respiratory acidosis and alkalosis[41] suggests
that albumin contributes 23% to the total buffering capacity[41] – despite
the Sprague-Dawley rat having equivalent haemoglobin[42] and bicarbonate
concentrations[43] and lower albumin[41] when compared to humans.
Ultimately, the consideration of phosphate and albumin as buffers de-
pends on whether clinical management is altered. Figure D1-3 summarises




































bicarbonate buffering and haemoglobin buffering
Slyke
Wooten
Multicomponent, bicarbonate buffering with explicit non− 
Figure D1-3: Venn diagram of clinical scenarios to which the
various acid-base approaches should apply
A benefit in the management of intensive care unit patients has not
been shown[33, 44] despite Stewart’s theory being able to detect hypoal-
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buminaemia masking an acidosis which is not recognised by base excess[33].
The equivalent of the anion gap in the traditional approach is the strong
ion gap (SIG) [33] which is defined by the difference between (D1-7) and
(D1-9)[26],
SIG = SIDapp − SIDeff . (D1-12)
SIG corrects for albumin and is more sensitive at detecting unmeasured
anions[33, 45]. Note that albumin’s contribution to SIG is 0.28 [Alb] (g/l)
from equations (D1-9) and (D1-8). No benefit has been demonstrated in
haemodiafiltration[46].
D1.5 Closing comments
The phenomenon of metabolic acidosis due to the infusion of sodium chlo-
ride cannot be explained by either the Henderson-Hasselbalch or Stewart ap-
proaches. It has been suggested that in normal (0.9%) saline [Na+] and [Cl−]
are equal whereas in plasma [Cl−] is less, thus the net effect of the infusion is a
reduction in SID and thus acidosis[34, 45]. From the Henderson-Hasselbalch
perspective, in vitro all the variables in (D1-3) are diluted and consequently
pH should be elevated (the difference between the [H+] and [OH−]) and in
vivo the reduction in [H+] is compensated by intracellular [H+] displacement
and respiration. Similarly, from the Stewart perspective, in vitro [H+], SID
and AT OT are all reduced which is measured as an elevation in pH while
in vivo the displacement of intracellular [H+] and respiratory compensation
should result in alkalosis. These findings are obvious given that, depending
on the approach, SID − AT OT is a proxy measure of HCO−3 or vice versa.
Sodium chloride in solution has a pH of 6.7− 7.3 which is lower than whole
blood pH.
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The fundamental difference between the Henderson-Hasselbalch and Stew-
art approaches is that the latter considers the effect of partially dissociated
ions (non-carbonate buffers/’weak acids’). The effect of albumin is not con-
sidered significant but this has not been shown explicitly. Although the in
vitro buffer capacity experiment[40] and the rat model[41] suggest a greater
role for non-bicarbonate buffering, the implicit constraints of the rat exper-
imental design still leaves a space to question the in vivo buffering capacity
of bicarbonate and the relative contribution of the non-bicarbonate buffers.
The absence of clear evidence of clinical benefit of the physicochemical
over the bicarbonate approach can potentially be explained as either the
contribution of plasma proteins is insignificant or, given that haemoglobin
contributes 79% of the total buffering, both the physicochemical approach
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D2: Dissertation proofs
D2.1 Proof that independent variables do not
imply and are not implied by regulated
factors
Here proof by contradiction is used. Two possible scenarios are explored.
Assume that dependent variables imply and are implied by regulated factors.
Assume that plasma CO2 is unregulated. PCO2 can be measured directly
with a CO2 electrode. Thus an example has been provided of an unregulated
factor being associated with an independent variable.
Conversely, assume that plasma CO2 is regulated. PCO2 can be mea-
sured directly with a CO2 electrode. Thus an example has been provided of
a regulated factor being associated with an independent variable.
Thus examples have been provided where an independent variable can be
associated with both regulated and unregulated factors. Thus independent
variables do not imply and are not implied by regulated factors.
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D2.2 Proof that dependent variables do not
imply and are not implied by unregu-
lated factors
Two possible cases are explored and proof by contradication is employed.
Assume that independent variables imply and are implied by regulated fac-
tors. Assume that plasma CO2 is regulated. Ignoring the contribution of
quantitatively smaller carbonate species, the total CO2 can be defined as
tCO2 = HCO−3 + CO2. (D2-1)
Given Reaction <D1-1>, in an acidic environment all the HCO−3 is reduced
to CO2 – allowing tCO2 to be measured by a CO2 electrode. Thus (D1-3)
and (D2-1) form a system of equations in two unknowns (dependent vari-
ables – HCO−3 , CO2) and pH and tCO2 are independent variables. Thus
an example has been provided where a dependent variable (CO2) implies a
regulated factor (CO2).
Conversely, assume that plasma CO2 is unregulated. Again (D1-3) and
(D2-1) form a system of equations in two unknowns (dependent variables –
HCO−3 , CO2) and pH and tCO2 are independent variables. Thus an example
has been provided where a dependent variable (CO2) implies an unregulated
factor (CO2).
Thus examples have been provided where a dependent variable can be
associated with both regulated and unregulated factors. Thus dependent
variables do not imply and are not implied by unregulated factors.
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D2.3 Proof that Stewart’s theory is not a spe-
cial case of Lewis acid-base theory
Stewart’s theory calculates [H+] as a function of the difference between an-
ions and cations[1]. Thus equimolar amounts of aqueous CaCl2 or NiCl2
should produce the same pH. However, aqueous CaCl2 is alkaline[2] and
aqueous NiCl2 is acidic[3] – compounds that Lewis’ theory was designed to
address.
D2.4 Proof that the number of potential states
can be increased arbitrarily
By definition
SID = [Na+] + [K+] + [Ca2+] + [Mg2+]− [Cl−]. (D2-2)
Let, without loss of generality,
SID−Na = SID − [Na+]. (D2-3)
Thus, substituting (D2-3) into (D1-11),
pH = pK1 + log
[Na+] + SID−Na − [A−T OT ]
sCO2 × PCO2
. (D2-4)
Equation (D2-4) has four independent variables and one dependent variable
and consequently has eighty-one potential states. Thus separating the indi-
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D3: Lewis acid-base theory
D3.1 Introduction
Before introducing the Lewis acid-base theory, one has to remove pre-conceived
acid base theories. Firstly, one should not think of acids and bases in terms
of H+. At the most basic level, acids change blue plant dyes to red and bases
negate (or neutralise) this effect[1]. This phenomenon will be called the acid-
base phenomenon and if the phenomenon occurs, the acid-base phenomenon
criteria are fulfilled.
Arrhenius and Brønstead-Lowry identified a subset of compounds that
could fulfill the acid-base phenomenon criteria. The subset of compounds
identified by these authors all contained H+ and consequently acid-base the-
ories were constructed based on this subset of molecules and H+. The defi-
nition of acids as proton (H+) donors are a construct of these theories and
apply to this particular subset of molecules. The definition and theory are
inseparable and the definition only applies to hydrogen containing molecules
that satisfy the acid-base phenomenon criteria.
It must be recognised that the molecules identified by the protoncentric
theories collectively form a subset of the superset of molecules satisfying
the acid-base phenomenon criteria. In particular, non-hydrogen containing
molecules can be shown to satisfy the acid-base phenomenon. Thus, by
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observing molecules that satisfy the acid-base phenomenon, a larger subset
of molecules are identified by the Lewis acid-base theory. The protoncentric
molecules form a subset of the Lewis acids and bases. The theory constructed
by Lewis defines an acid as a species that can form a covalent bond[2] by
accepting an electron pair from another species[3]. A Lewis acid reacts with
a Lewis base to form an adduct. All metal cations act as a Lewis acid when
dissolved in water[2, 3] with the typical reaction
M2+︸ ︷︷ ︸
acid






where M2+ is the metal cation and need not be of charge 2+.
D3.2 Proof that H+ is a Lewis acid
When considering Reaction <D3-1>, it is evident that H+ could be consid-
ered to be a metal cation. In such a case, it is evident that Arrhenius acids










where H3O+ is Arrhenius’ hydronium ion.
Alternatively, hydrochloric acid is formed from the electron pair donor
Cl− which is a Brønstead-Lowry base and the electron pair acceptor H+ – a






 HCl︸ ︷︷ ︸
adduct
<D3-3>
where HCl is covalently bonded.
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D3.3 Proof that Lewis acids are acidic
The title can be rephrased as: “proof that Lewis acids cause an increase in
[H+]” and hence a paradox. The requirement for an increase in [H+] is a
requirement of theory which is contained within the Lewis acid-base theory
and only applies to a subset of Lewis acids and bases.
It cannot generally be shown that Lewis acids cause an increase in [H+]
– and it is not necessary. Acids do not need to increase [H+], they only need
to satisfy the acid-base phenomenon criteria.
Given that Lewis acids are a superset of the protoncentric models, it can
always be shown that Arrhenius and Brønstead Lowry acids are examples of
Lewis acids – and are thus acidic by the broader definition of Lewis acids.
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D4: Urine bicarbonate decision
limits
D4.1 Calculation of urine bicarbonate deci-
sion limit







where UCr ≈ 2.4mmol/L was arbitrarily selected as the urine creatinine
concentration, SCr ≈ 0.1mmol/L is the serum creatinine concentration and
SHCO−3
≥ 22mmol/L is the minimum serum bicarbonate concentration re-
quired to calculate the FeHCO−3 [1, 2]. The decision limit is defined by a
FeHCO−3 of 5% – below which one diagnoses RTA I.






= 0.05×22×2.450.1 = 27mmol/L. (D4-2)
Thus the urine bicarbonate decision limit will be 27mmol/L and half the
decision limit will be 13.5mmol/L.
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D4.2 Calculation of double urine bicarbonate
decision limit
Double the decision limit is defined by a FeHCO−3 of 10% – above which
one diagnoses RTA II[1, 2]. Substituting FeHCO−3 = 0.1 into (D4-2) one
calculates that
UHCO−3 = 0.1× 22×
2.45
0.1 = 54mmol/L (D4-3)
is double the urine bicarbonate decision limit.
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D9: External quality assurance
forms
D9-1 Proficiency testing instruction sheet
Attention:
Address of institution: HospLab
Dear Sir/madam
Thank you for participating in our urine bicarbonate external QA pro-
gram. This is sample 09/2010/HospLab and consists of 6 specimens.
Enclosed you should find 6 microcentrifuge tubes containing various amounts
of NaHCO3. Two are 0.5ml microcentrifuge tubes (can hold 550µl). Two
are 1.5ml microcentrifuge tubes (can hold 1650µl) and two are 2ml micro-
centrifuge tubes (can hold 2200µl). Each pair is labelled either 1 or 2. Below
is a table listing the volume of urine to be added to the labelled microcen-
trifuge tubes (ml and µl). A total of 8ml of urine will be required - note
that volumes required differ among microcentrifuge tubes.
Any human urine may be used provided only one urine patient sample is
used for all 6 specimens. Pooled urine can also be used. Tap the microcen-
D9-47
D9-48
Date Tube size/tube name Volume to Volume toadd (ml) add (µl)
30/09/2010
0.5ml 1 0.5.1 0.475 475
0.5ml 2 0.5.2 0.475 475
1.5ml 1 1.5.1 1.425 1425
1.5ml 2 1.5.2 1.35 1350
2.0ml 1 2.0.1 2.2 2200
2.0ml 2 2.0.2 1.9 1900
Total urine required ml 7.825
trifuge tubes to dislodge the NaHCO3 powder off the lid. Add the required
volumes of urine to the microcentrifuge tubes, vortex and measure total CO2.
Kindly return the results to me for analysis.
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